<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001939.pub4" GROUP_ID="LIVER" ID="355999081609390896" MERGED_FROM="" MODIFIED="2017-05-17 13:40:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.2">
<COVER_SHEET MODIFIED="2017-05-17 14:31:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-02-18 14:13:19 +0100" MODIFIED_BY="[Empty name]">Branched-chain amino acids for people with hepatic encephalopathy</TITLE>
<CONTACT>
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>MD, DMSc</SUFFIX>
<POSITION>Consultant</POSITION>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+45 38621964</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION>
<ADDRESS_1>Kettegaards Alle</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hvidovre</CITY>
<ZIP>2650</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 38621964</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-05-17 14:31:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>MD, DMSc</SUFFIX>
<POSITION>Consultant</POSITION>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+45 38621964</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION>
<ADDRESS_1>Kettegaards Alle</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hvidovre</CITY>
<ZIP>2650</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 38621964</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1308061409218003927857931196255" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gitte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dam</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>gitte_dam@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine V (Hepatology and Gastroenterology)</DEPARTMENT>
<ORGANISATION>Aarhus University Hospital</ORGANISATION>
<ADDRESS_1>44 Noerrebrogade</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aarhus C</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1308061412154653675527520396488" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Iñigo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Les</LAST_NAME>
<SUFFIX/>
<POSITION>Doctor of Medicine</POSITION>
<EMAIL_1>ilesbujanda@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>Hospital Universitario Araba</ORGANISATION>
<ADDRESS_1>C/ Olaguibel, 27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Vitoria-Gasteiz</CITY>
<ZIP>01004</ZIP>
<REGION>Álava</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>0034636346833</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1308061424253737952918272965830" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giulio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Marchesini</LAST_NAME>
<SUFFIX/>
<POSITION>Head, Unit of Metabolic Diseases and Clinical Dietetics</POSITION>
<EMAIL_1>giulio.marchesini@unibo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine, Alma Mater Studiorum</DEPARTMENT>
<ORGANISATION>University of Bologna</ORGANISATION>
<ADDRESS_1>9, Via Massarenti</ADDRESS_1>
<ADDRESS_2>S. Orsola-Maloighi Hospital</ADDRESS_2>
<CITY>Bologna</CITY>
<ZIP>40138</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 051 6364889</PHONE_1>
<PHONE_2/>
<FAX_1>+39 051 6364502</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1308061428003657108846858584647" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Mette</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Borre</LAST_NAME>
<SUFFIX/>
<POSITION>Dietitian</POSITION>
<EMAIL_1>mette.borre@aarhus.rm.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine V (Hepatology and Gastroenterology)</DEPARTMENT>
<ORGANISATION>Aarhus University Hospital</ORGANISATION>
<ADDRESS_1>44 Noerrebrogade</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aarhus C</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1308061421334260053223881579634" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Niels Kristian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Aagaard</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>nielaaga@rm.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine V (Hepatology and Gastroenterology)</DEPARTMENT>
<ORGANISATION>Aarhus University Hospital</ORGANISATION>
<ADDRESS_1>44 Noerrebrogade</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aarhus C</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6559" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Hendrik</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vilstrup</LAST_NAME>
<SUFFIX>Dr Med Sci</SUFFIX>
<POSITION>Professor</POSITION>
<EMAIL_1>vilstrup@clin.au.dk</EMAIL_1>
<EMAIL_2>hendrik.vilstrup@aarhus.rm.dk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Hepatology and Gastroenterology</DEPARTMENT>
<ORGANISATION>Aarhus Kommunehospital</ORGANISATION>
<ADDRESS_1>Nørrebrogade 44</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aarhus C</CITY>
<ZIP>DK-8000</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 7846 3891</PHONE_1>
<PHONE_2/>
<FAX_1>+45 8949 2860</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-05-17 14:31:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="5" MONTH="5" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="5" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="5" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-05-10 13:41:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-10 13:40:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="5" MONTH="5" YEAR="2017"/>
<DESCRIPTION>
<P>New search conducted. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-05-10 13:41:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="5" MONTH="5" YEAR="2017"/>
<DESCRIPTION>
<P>No additional trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-05-10 13:32:44 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2011-03-09 17:57:52 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-03-09 17:57:24 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-03-09 17:57:24 +0100" MODIFIED_BY="[Empty name]">
<NAME>No funding</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-03-09 17:57:52 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-03-09 17:57:52 +0100" MODIFIED_BY="[Empty name]">
<NAME>No funding</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-05-17 14:38:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2015-09-08 12:44:07 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-06-05 08:01:31 +0200" MODIFIED_BY="[Empty name]">Branched-chain amino acids improve symptoms of hepatic encephalopathy</TITLE>
<SUMMARY_BODY MODIFIED="2015-09-08 12:44:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Hepatic encephalopathy is a brain dysfunction associated with liver disease. Cirrhosis, which is a condition where scar tissue (fibrosis) replaces the normal liver tissue, is the most common cause of hepatic encephalopathy. The severity of the symptoms range from minor signs to coma. The minor changes are known as minimal hepatic encephalopathy. Overt hepatic encephalopathy refers to the more severe stages with clinically apparent manifestations such as changes in the level of consciousness or neuropsychiatric abnormalities. Many people with cirrhosis lack amino acids, which are building blocks of proteins. The amino acids with a side-chain (a branch) are known as branched-chain amino acids (BCAA). The BCAA play an important part of the generation muscles and of the signalling chemicals in the brain. These effects may benefit people with hepatic encephalopathy.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We identified 16 randomised clinical trials (trials where participants are randomly allocated to treatment groups) including 827 participants. The included people had cirrhosis often due to alcoholic liver disease or viral hepatitis (liver infection due to a virus). The trials compared BCAA with placebo (a pretend treatment), no intervention, diets, lactulose (a liquid sugar often used to treat constipation), or neomycin (an antibiotic). The evidence is current to October 2014.</P>
<P>
<B>Key results</B>
</P>
<P>The analyses found no effect on mortality, but that BCAA had a beneficial effect on symptoms and signs of hepatic encephalopathy. BCAA did not increase the risk of serious adverse events, but was associated with nausea and diarrhoea. When excluding trials on lactulose or neomycin, BCAA had a beneficial effect on hepatic encephalopathy. When analysing trials with a lactulose or neomycin control, we found no beneficial or detrimental effect of BCAA.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We assessed the quality of the evidence to evaluate aspects that can lead to errors in the judgment of intervention effects. We concluded that we had high quality evidence in our analyses about the effect of BCAA on hepatic encephalopathy. We concluded that we had moderate or low quality evidence in the remaining analyses because the number of participants in the trials was too small and the risk of bias (systematic errors) was unclear or high.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-05-10 10:17:05 +0200" MODIFIED_BY="Sarah  Klingenberg">
<ABS_BACKGROUND MODIFIED="2015-02-23 12:02:05 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Hepatic encephalopathy is a brain dysfunction with neurological and psychiatric changes associated with liver insufficiency or portal-systemic shunting. The severity ranges from minor symptoms to coma. A Cochrane systematic review including 11 randomised clinical trials on branched-chain amino acids (BCAA) versus control interventions has evaluated if BCAA may benefit people with hepatic encephalopathy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-02-18 14:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the beneficial and harmful effects of BCAA versus any control intervention for people with hepatic encephalopathy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-05-10 10:17:05 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>We identified trials through manual and electronic searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded and Conference Proceedings Citation Index &#8211; Science, and LILACS (May 2017).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-02-18 14:17:19 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised clinical trials, irrespective of the bias control, language, or publication status.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-02-18 14:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>The authors independently extracted data based on published reports and collected data from the primary investigators. We changed our primary outcomes in this update of the review to include mortality (all cause), hepatic encephalopathy (number of people without improved manifestations of hepatic encephalopathy), and adverse events. The analyses included random-effects and fixed-effect meta-analyses. We performed subgroup, sensitivity, regression, and trial sequential analyses to evaluate sources of heterogeneity (including intervention, and participant and trial characteristics), bias (using The Cochrane Hepato-Biliary Group method), small-study effects, and the robustness of the results after adjusting for sparse data and multiplicity. We graded the quality of the evidence using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-08 12:53:47 +0200" MODIFIED_BY="[Empty name]">
<P>We found 16 randomised clinical trials including 827 participants with hepatic encephalopathy classed as overt (12 trials) or minimal (four trials). Eight trials assessed oral BCAA supplements and seven trials assessed intravenous BCAA. The control groups received placebo/no intervention (two trials), diets (10 trials), lactulose (two trials), or neomycin (two trials). In 15 trials, all participants had cirrhosis. We classed seven trials as low risk of bias and nine trials as high risk of bias (mainly due to lack of blinding or for-profit funding). In a random-effects meta-analysis of mortality, we found no difference between BCAA and controls (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.69 to 1.11; 760 participants; 15 trials; <I>moderate quality of evidence</I>)<I>. </I>We found no evidence of small-study effects. Sensitivity analyses of trials with a low risk of bias found no beneficial or detrimental effect of BCAA on mortality. Trial sequential analysis showed that the required information size was not reached, suggesting that additional evidence was needed. BCAA had a beneficial effect on hepatic encephalopathy (RR 0.73, 95% CI 0.61 to 0.88; 827 participants; 16 trials; <I>high quality of evidence</I>)<I>. </I>We found no small-study effects and confirmed the beneficial effect of BCAA in a sensitivity analysis that only included trials with a low risk of bias (RR 0.71, 95% CI 0.52 to 0.96). The trial sequential analysis showed that firm evidence was reached. In a fixed-effect meta-analysis, we found that BCAA increased the risk of nausea and vomiting (RR 5.56; 2.93 to 10.55; <I>moderate quality of evidence</I>). We found no beneficial or detrimental effects of BCAA on nausea or vomiting in a random-effects meta-analysis or on quality of life or nutritional parameters. We did not identify predictors of the intervention effect in the subgroup, sensitivity, or meta-regression analyses. In sensitivity analyses that excluded trials with a lactulose or neomycin control, BCAA had a beneficial effect on hepatic encephalopathy (RR 0.76, 95% CI 0.63 to 0.92). Additional sensitivity analyses found no difference between BCAA and lactulose or neomycin (RR 0.66, 95% CI 0.34 to 1.30).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-02-18 14:18:54 +0100" MODIFIED_BY="[Empty name]">
<P>In this updated review, we included five additional trials. The analyses showed that BCAA had a beneficial effect on hepatic encephalopathy. We found no effect on mortality, quality of life, or nutritional parameters, but we need additional trials to evaluate these outcomes. Likewise, we need additional randomised clinical trials to determine the effect of BCAA compared with interventions such as non-absorbable disaccharides, rifaximin, or other antibiotics.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-05-10 13:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2017-05-10 12:46:16 +0200" MODIFIED_BY="Sarah  Klingenberg">
<CONDITION MODIFIED="2015-02-18 15:01:36 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatic encephalopathy is a brain dysfunction associated with significant liver insufficiency or portal-systemic shunting (<LINK REF="REF-Guerit-2009" TYPE="REFERENCE">Guerit 2009</LINK>; <LINK REF="REF-Randolph-2009" TYPE="REFERENCE">Randolph 2009</LINK>; <LINK REF="REF-Bajaj-2011" TYPE="REFERENCE">Bajaj 2011</LINK>). The symptoms include neurological and psychiatric changes and the severity ranges from minor symptoms to coma (<LINK REF="REF-Blei-2001" TYPE="REFERENCE">Blei 2001</LINK>). People with minimal hepatic encephalopathy have no clinically overt signs, but have neuropsychiatric deficiencies that are diagnosed through psychometric tests (<LINK REF="REF-Amodio-2008" TYPE="REFERENCE">Amodio 2008</LINK>). Overt hepatic encephalopathy in people with cirrhosis generally occurs due to an event such as variceal bleeding or infections. Mortality approaches 50% among people who are hospitalised with severe hepatic encephalopathy (<LINK REF="REF-Fichet-2009" TYPE="REFERENCE">Fichet 2009</LINK>), and 3% to 14% among people diagnosed with minimal hepatic encephalopathy (<LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>). Both overt and minimal hepatic encephalopathy are associated with physical symptoms and have a considerable impact on the quality of life (<LINK REF="REF-Wein-2004" TYPE="REFERENCE">Wein 2004</LINK>; <LINK REF="REF-Bajaj-2008" TYPE="REFERENCE">Bajaj 2008</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-02-18 15:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>The three branched-chain amino acids (BCAA) leucine, isoleucine, and valine are essential amino acids with a carbon chain (<LINK REF="REF-Holecek-2010" TYPE="REFERENCE">Holecek 2010</LINK>). Nutritional supplements containing BCAA can be administered orally or intravenously. The available products also differ in terms of the content as is illustrated in randomised clinical trials on BCAA with products containing different amounts of BCAA (<LINK REF="STD-Malaguarnera-2009" TYPE="STUDY">Malaguarnera 2009</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>; <LINK REF="REF-Amodio-2014" TYPE="REFERENCE">Amodio 2014</LINK>; <LINK REF="REF-Roman-2014" TYPE="REFERENCE">Roman 2014</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-02-18 15:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>The pathogenesis of hepatic encephalopathy is not completely understood. Ammonia plays a central role (<LINK REF="REF-Holecek-2014" TYPE="REFERENCE">Holecek 2014</LINK>). Most interventions for hepatic encephalopathy are directed against a reduction of ammonia (<LINK REF="REF-Wright-2007" TYPE="REFERENCE">Wright 2007</LINK>; <LINK REF="REF-Garcia_x002d_Martinez-2011" TYPE="REFERENCE">Garcia-Martinez 2011</LINK>). Hyperammonaemia is one of the main causes of decreased levels of BCAA in liver cirrhosis (<LINK REF="REF-Holecek-2011" TYPE="REFERENCE">Holecek 2011</LINK>). In cirrhosis, BCAA are consumed in skeletal muscle (<LINK REF="REF-Dam-2011" TYPE="REFERENCE">Dam 2011</LINK>; <LINK REF="REF-Holecek-2013" TYPE="REFERENCE">Holecek 2013</LINK>). Biochemically, BCAA supply muscle tissue with carbon skeletons for replenishment of &#945;-ketoglutarate, which may be depleted during hyperammonaemia through enhanced amination to glutamate and, subsequently, amidation of glutamate to glutamine. BCAA and glutamate concentrations in plasma and muscle tissue are reduced in people with cirrhosis and hyperammonaemia, and the removal of ammonia in muscle is proportional to the removal of BCAA in people with cirrhosis. Skeletal muscle is believed to play a key role in ammonia detoxification in people with cirrhosis and several studies have indicated that BCAA enhance this detoxification (<LINK REF="REF-Dam-2011" TYPE="REFERENCE">Dam 2011</LINK>; <LINK REF="REF-Holecek-2013" TYPE="REFERENCE">Holecek 2013</LINK>). However, the effects of BCAA supplements are complex. BCAA supplementation may reduce malnutrition and revert the loss of muscle cell mass that is common in severe liver disease and the breakdown of protein that occurs in people with hepatic encephalopathy (<LINK REF="REF-C_x00f3_rdoba-2004" TYPE="REFERENCE">Córdoba 2004</LINK>; <LINK REF="REF-Kachaamy-2011" TYPE="REFERENCE">Kachaamy 2011</LINK>). The increased muscle mass may increase extrahepatic ammonia detoxification (<LINK REF="REF-Olde-2002" TYPE="REFERENCE">Olde 2002</LINK>). Glutamine synthetase activity is high in muscle tissue, which promotes detoxification of ammonia to glutamine. BCAA supplementation also increases plasma levels of BCAA and reduce the ratio between aromatic amino acids and BCAA (<LINK REF="REF-Holecek-2010" TYPE="REFERENCE">Holecek 2010</LINK>). BCAA may further enhance detoxification of ammonia in skeletal muscle by the amidation process for glutamine synthesis (<LINK REF="REF-Kawaguchi-2013" TYPE="REFERENCE">Kawaguchi 2013</LINK>). The addition of BCAA reduces cerebral efflux of aromatic amino acids across the blood-brain barrier and the imbalance of the synthesis of dopamine, noradrenaline, and serotonin (<LINK REF="REF-Bak-2006" TYPE="REFERENCE">Bak 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-05-10 12:46:16 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>Cognitive impairment associated with cirrhosis results in larger utilisation of healthcare resources in adults more than any other manifestations of liver disease (<LINK REF="REF-Rakoski-2012" TYPE="REFERENCE">Rakoski 2012</LINK>). Diagnostic tools range from simple scales to sophisticated psychometric tests. The value of the individual tools and the selection of the best diagnostic strategy depend on the clinical situation. Accordingly, investigators in clinical trials on hepatic encephalopathy have used a variety of scales and tests in their assessments of the diagnosis and improved manifestations of hepatic encephalopathy (<LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). The assessment of clinically relevant improvement in hepatic encephalopathy is an essential outcome, irrespective of the severity of symptoms (<LINK REF="REF-Bajaj-2010" TYPE="REFERENCE">Bajaj 2010</LINK>; <LINK REF="REF-Bajaj-2011" TYPE="REFERENCE">Bajaj 2011</LINK>; <LINK REF="REF-AASLD-and-EASL-guideline-2014a" TYPE="REFERENCE">AASLD and EASL guideline 2014a</LINK>; <LINK REF="REF-AASLD-and-EASL-guideline-2014b" TYPE="REFERENCE">AASLD and EASL guideline 2014b</LINK>). Based on the available evidence, the 2014 joint guidelines from the American Association for the Study of Liver Diseases (<LINK REF="REF-AASLD-and-EASL-guideline-2014a" TYPE="REFERENCE">AASLD and EASL guideline 2014a</LINK>), and the European Association for the Study of the liver (<LINK REF="REF-AASLD-and-EASL-guideline-2014b" TYPE="REFERENCE">AASLD and EASL guideline 2014b</LINK>), recommend treatment of any precipitating factors and non-absorbable disaccharides as the initial treatment. The guidelines recommend BCAA as an alternative or additional agent to treat people who do not respond to the initial therapy. Previous meta-analyses of randomised trials and observational studies suggested that the evidence on BCAA supplements is inconclusive due to methodological concerns, small sample sizes, and short follow-up (<LINK REF="REF-Tygstrup-1984" TYPE="REFERENCE">Tygstrup 1984</LINK>; <LINK REF="REF-Naylor-1989" TYPE="REFERENCE">Naylor 1989</LINK>; <LINK REF="REF-Gluud-1991" TYPE="REFERENCE">Gluud 1991</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2003" TYPE="REFERENCE">Als-Nielsen 2003</LINK>; <LINK REF="REF-Metcalfe-2014" TYPE="REFERENCE">Metcalfe 2014</LINK>). Subsequent randomised trials are likely to contain important new information (<LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). In particular, systematic reviews on intervention for hepatic encephalopathy found essential information on orally administered BCAA supplements (<LINK REF="REF-Gluud-2013a" TYPE="REFERENCE">Gluud 2013a</LINK>; <LINK REF="REF-Gluud-2013b" TYPE="REFERENCE">Gluud 2013b</LINK>). Therefore, we performed this updated systematic review. In the updated review, we changed the methods and reporting to reflect current guidelines in the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>), the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>), and the Methodological Expectations of Cochrane Intervention Reviews (MECIR) guidelines (<LINK REF="REF-MECIR-2014" TYPE="REFERENCE">MECIR 2014</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-02-18 15:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the beneficial and harmful effects of BCAA versus any control intervention for people with hepatic encephalopathy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-05-10 13:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2017-05-10 12:46:16 +0200" MODIFIED_BY="Sarah  Klingenberg">
<CRIT_STUDIES MODIFIED="2014-12-20 00:52:43 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised clinical trials irrespective of blinding, publication status, or language in our primary analyses and attempted to identify quasi-randomised and observational studies for the analyses of adverse events.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>People with overt or minimal hepatic encephalopathy associated with acute or chronic liver disease (<LINK REF="REF-AASLD-and-EASL-guideline-2014a" TYPE="REFERENCE">AASLD and EASL guideline 2014a</LINK>; <LINK REF="REF-AASLD-and-EASL-guideline-2014b" TYPE="REFERENCE">AASLD and EASL guideline 2014b</LINK>). The diagnosis could be made based on clinical evaluations (e.g., using standardised scores), psychometric and neurophysiological scores, electroencephalography, or laboratory testing (ammonia). We based the diagnosis on the criteria reported in the individual trials.<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-02-18 15:08:02 +0100" MODIFIED_BY="[Empty name]">
<P>Any form of BCAA, irrespective of dose or duration. People in the control groups could receive placebo, no intervention, diets, non-absorbable disaccharides, antibiotics, or any other intervention with a potential effect on hepatic encephalopathy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-05-10 12:46:16 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>As recommended (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>), we included adverse events as our primary outcome measure and changed all outcomes to unwanted events (when possible). We evaluated outcomes at the maximum duration of follow-up.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-02-18 15:08:15 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Mortality (all-cause).</LI>
<LI>Hepatic encephalopathy (number of people without improved manifestations of hepatic encephalopathy).</LI>
<LI>Adverse events: any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability or incapacity, or was a congenital anomaly/birth defect, or any medical event that might have jeopardised the person, or required intervention to prevent it (<LINK REF="REF-ICH-GCP-1997" TYPE="REFERENCE">ICH GCP 1997</LINK>).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov">
<OL>
<LI>Quality of life.</LI>
<LI>Markers of nutritional status including albumin and nitrogen balance (the nitrogen input minus the nitrogen output).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-05-10 13:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-05-10 13:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We performed the electronic searches in the Cochrane Hepato-Biliary Group Controlled Trials Register (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>), the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase Ovid, Science Citation Index Expanded and Conference Proceedings Citation Index &#8211; Science (Web of Science), and Lilacs (Bireme) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> displays the search strategies with the time spans of the searches. We did not have access to Chinese, Russian, and Japanese databases, which is a limitation when searching for randomised trials of possible interest to the review. We hope that helped by The CHBG Trials Search Co-ordinator, we will be able to search for further trials also in these databases next time when we update our review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-05-05 16:19:46 +0200" MODIFIED_BY="[Empty name]">
<P>The authors conducted manual searches included scanning of reference lists in relevant papers, specialist journals, conference proceedings, and searches in the World Health Organization online trial meta-register (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>). We also searched Google Scholar (using the terms 'branched chain amino acids' AND 'cirrhosis* AND random*) and wrote to experts for information about any additional published or unpublished trials. </P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-05-10 12:53:38 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>At least two authors (LG, GD, and GB) independently extracted data from the published trial reports. We wrote to authors of included trials for additional information including data that would allow recalculation of outcomes when necessary. For trials described in more than one record, we used the record with the most complete information (the largest number of participants and events and the longest duration of follow-up).</P>
<STUDY_SELECTION MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>We listed trials identified through the electronic and manual searches, selected trials using the criteria described above and listed excluded trials with the reason for exclusion (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-02-18 15:11:33 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted the following data:</P>
<UL>
<LI>participant characteristics: inclusion criteria, mean age, proportion of men, and type of underlying liver disease;</LI>
<LI>intervention characteristics: type, dose, and duration of interventions;</LI>
<LI>trial characteristics: setting (hospital or outpatient), number of clinical sites, country of origin, patient inclusion period, and funding.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-05-10 12:46:16 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>Authors independently assessed the risk of bias in included trials based on individual domains according to the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>). We classed each domain as having a low, uncertain, or high risk of bias based on the definitions described below. As recommended, we included an analysis that combined all domains and categorised trials as low risk of bias if none of the domains were classed as high or unclear risk of bias. </P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial.</LI>
<LI>Unclear risk of bias: the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method was not random.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g., if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants, personnel, and outcome assessors</HEADING>
<UL>
<LI>Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding. We defined the outcome all-cause mortality and laboratory assessments as unlikely to be influenced by lack of blinding (<LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>).</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results.</LI>
<LI>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes were likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessors</HEADING>
<UL>
<LI>Low risk of bias: outcome assessment was carried out blinded for all relevant outcomes, and the method of blinding was described, so that knowledge of allocation was prevented.</LI>
<LI>Unclear risk of bias: blinding of outcome assessment was not described, or the outcome assessment was described as blinded, but the method of blinding was not described, so that knowledge of allocation was possible.</LI>
<LI>High risk of bias: outcome assessment was not blinded, so that the allocation was known to outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data.</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk: the trial reported mortality and hepatic encephalopathy. If the original trial protocol was available, the outcomes should have been those called for in that protocol.</LI>
<LI>Unclear risk: it was unclear whether data on the pre-defined outcomes were recorded or not.</LI>
<LI>High risk: one or more of the pre-defined outcomes were not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design, conductance, or results of the trial.</LI>
<LI>Unclear risk of bias: the trial may or may not be free of for-profit bias as no information on clinical trial support or sponsorship was provided.</LI>
<LI>High risk of bias: the trial was sponsored by industry or received other type of for-profit support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other bias including vested interests and medicinal dosing problems that could put it at risk of bias.</LI>
<LI>Unclear risk of bias: there was insufficient information to determine if the trial was free of other biases.</LI>
<LI>High risk of bias: there were factors in the trial that could put it at risk of bias: for example, funding from a for-profit organisation or the administration of inappropriate treatment was given to the controls (such as an inappropriate dose).</LI>
</UL>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-02-18 15:12:44 +0100" MODIFIED_BY="[Empty name]">
<P>We used risk ratio (RR) for dichotomous outcomes and standardised mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-02-18 15:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>For cross-over trials, we only used data from the first treatment period. For trials with more than one control group (e.g., trials with two different control diets), we combined data from the two control groups.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-02-18 15:13:05 +0100" MODIFIED_BY="[Empty name]">
<P>We gathered data to allow intention-to-treat analyses. Our analyses included data on all participants randomised, irrespective of compliance, protocol violations, or follow-up. We used simple imputation to evaluate the potential influence of missing data (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The analyses included missing values counted as failures or successes using the following strategies:</P>
<UL>
<LI>all participants with missing data counted as failures;</LI>
<LI>participants with missing outcome data in the BCAA arm counted as failures and in the control arm as successes.</LI>
</UL>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-02-18 15:13:16 +0100" MODIFIED_BY="[Empty name]">
<P>We expressed heterogeneity as I<SUP>2 </SUP>values using the thresholds: 0% to 40% (unimportant), 40% to 60% (moderate), 60% to 80% (substantial), and greater than 80% (considerable).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-09-08 12:46:28 +0200" MODIFIED_BY="[Empty name]">
<P>For meta-analyses with at least 10 trials, we assessed reporting biases and other dissemination biases based on analyses of small-study effects (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>) using the Harbord modified test for dichotomous outcomes and Egger tests for continuous outcomes (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>). We also attempted to obtain trial protocols to compare reported outcome measures in the protocol and published trial. The Harbord test regresses Z/sqrt(V) against sqrt(V), where Z was the efficient score and V was Fisher's information (the variance of Z under the null hypothesis). The Egger test performs a linear regression of the intervention effect estimates on their standard errors, weighing by 1/(variance of the intervention effect estimate). We reported the result as P values.<BR/>
</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-05-10 12:53:38 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>We performed our analyses using Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), STATA (<LINK REF="REF-Stata-13" TYPE="REFERENCE">Stata 13</LINK>), and trial sequential analysis (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Meta-analysis</HEADING>
<P>We performed random-effects and fixed-effect meta-analyses, but only reported the results of the fixed-effect meta-analyses if the result of the two models differed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>We performed a trial sequential analysis for the outcome measures mortality and hepatic encephalopathy using random-effects models with alpha set to 5%, power to 80%, and model-based heterogeneity (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We defined the required information size as the number of participants needed to detect or reject an intervention effect estimate based on the event proportion in the control group, the observed relative risk reduction (RRR), and the diversity of the meta-analysis (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). We constructed trial sequential monitoring boundaries (the inward sloping red lines) based on the required information size and defined firm evidence as being established if the Z-curve (the result of the cumulative meta-analysis) crossed the monitoring boundary and the required information size (the vertical red line at the end of the graph). In the analysis of mortality, we set alpha to 5%, power to 80%, control group event rate to 25%, RRR to 5%, and heterogeneity correction to 17%. In the analysis of hepatic encephalopathy, we set alpha to 5%, power to 80%, control group event rate to 63%, RRR to 45%, and heterogeneity correction to 47%. To account for the risk of overestimation of intervention effects due to bias (<LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>), we also conducted the analysis with the control group event rate set to 45% and RRR set to 35% for hepatic encephalopathy.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov">
<P>Subgroup analyses (reported using the P value based on test for subgroup differences):</P>
<UL>
<LI>type of hepatic encephalopathy (overt or minimal);</LI>
<LI>mode of administration (oral or intravenous);</LI>
<LI>type of control group (e.g., placebo/no intervention, diets, non-absorbable disaccharides or antibiotics).</LI>
</UL>
<P>We used univariable meta-regression analyses to evaluate the potential influence of continuous trial characteristics (e.g., the dose of BCAA and the duration of therapy) for meta-analyses with at least 10 trials.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-02-18 15:17:13 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the robustness of the overall results, we repeated our analyses:</P>
<UL>
<LI>including only trials with a low risk of bias based on individual domains;</LI>
<LI>comparing trials published in abstract form or as full-paper article;</LI>
<LI>comparing the re-calculated outcomes based on individual participant data or published data.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Exploratory (post-hoc) analyses</HEADING>
<P>Based on peer-review comments, we performed sensitivity analysis in which we excluded:</P>
<UL>
<LI>trials that included people with or without cirrhosis;</LI>
<LI>trials with a lactulose or neomycin control group;</LI>
<LI>trials with a placebo/no intervention or diet control group (i.e., only included trials with a lactulose or neomycin control group).</LI>
</UL>
<P>We also performed univariable and multivariable random-effects meta-regression analyses to evaluate predictors of heterogeneity including characteristics of the experimental intervention (the dose, duration, and mode of administration), the control intervention (type of control group), and participant characteristics (proportion of men, mean age, proportion of participants with cirrhosis, and type of hepatic encephalopathy).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' tables</HEADING>
<P>We included a <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) prepared using GRADE software (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>) with information on the results of our primary outcomes in relation to the quality of the evidence based on the risk of heterogeneity, indirectness, imprecision, risk of bias, and publication bias.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-05-05 16:10:17 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-05-05 16:10:17 +0200" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>We include 16 randomised clinical trials in the qualitative and quantitative analyses (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). The trials included 827 participants with hepatic encephalopathy (97% had cirrhosis). The type of hepatic encephalopathy was minimal in four trials (<LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>), and overt in the remaining 12 trials. Eight trials assessed oral BCAA for minimal or overt hepatic encephalopathy (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). Seven trials assessed intravenous BCAA for overt hepatic encephalopathy (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>). One trial assessed oral or intravenous BCAA versus a control diet for overt hepatic encephalopathy (<LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>). In the eight trials studying oral BCAA, people in the control group received placebo/no intervention or diets. In the seven trials studying intravenous BCAA, people in the control groups received placebo/no intervention or diets (<LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>), neomycin (<LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>), or lactulose (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>).</P>
<SEARCH_RESULTS MODIFIED="2017-05-05 16:10:17 +0200" MODIFIED_BY="[Empty name]">
<P>We identified 1196 potentially relevant records in the electronic searches and 20 additional records in the manual searches (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Of these, 40 records that referred to 16 randomised clinical trials fulfilled our inclusion criteria. We found one trial published in abstract form (<LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>), and 15 trials described in full paper articles (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). We were able to obtain unpublished information about the trial design (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and data that allowed re-calculation of outcomes based on the individual participant data for four trials (<LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). Four authors of the present review (IL, JC, GM, and HV) were investigators on included randomised clinical trials (<LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-09-08 11:27:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Participants</B>
</P>
<P>The trials included 827 participants with hepatic encephalopathy. None used BCAA deficiency in their inclusion or exclusion criteria. Most participants (97%) had cirrhosis. The proportion of men ranged from 47% to 90%, the proportion of people with alcoholic liver disease ranged from 8% to 100%, and the proportion of people with viral hepatitis ranged from 0% to 81%. The mean age ranged from 47 to 64 years. In four trials, 6% to 74% of people had hepatic encephalopathy at baseline (we only included data on the people with hepatic encephalopathy in our analyses) (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). The type of hepatic encephalopathy was minimal in four trials (<LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>), and overt in the remaining 11 trials (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>).</P>
<P>
<B>Interventions </B>
</P>
<P>In one trial, most participants received oral BCAA and people who deteriorated received intravenous BCAA (<LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>). Seven trials assessed oral BCAA (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>), or intravenous BCAA (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>). Trials studying intravenous BCAA treated people in hospital and the remainder on an outpatient basis. The dose of BCAA ranged from 11 g/day to 57 g/day (median 20 g/day) and treatment duration from one to 104 weeks (median four weeks).</P>
<P>
<B>Comparisons </B>
</P>
<P>The control groups received placebo/no intervention in two trials (<LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>). The type of BCAA in these two trials was oral (<LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>), or intravenous (<LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>). In 10 trials, participants were allocated to BCAA versus diets (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). The experimental intervention in these trials was oral BCAA (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>), or intravenous BCAA (<LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>). Four trials compared intravenous BCAA versus lactulose (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>), or neomycin (<LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>).</P>
<P>
<B>Outcomes</B>
</P>
<P>One trial did not report mortality (<LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>). The remaining trials reported mortality at the end of treatment. All trials reported the effect of BCAA on hepatic encephalopathy. Twelve trials assessed the effect of BCAA on manifestations of overt hepatic encephalopathy (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>), and four trials of minimal hepatic encephalopathy (<LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-02-18 15:18:47 +0100" MODIFIED_BY="[Empty name]">
<P>The excluded trials were quasi-randomised studies in which different BCAA regimens were compared, or people without hepatic encephalopathy were assessed (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). We were unable to gather data on adverse events from these studies. We did not identify any ongoing trials.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>The assessment of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) included information retrieved from the published trial reports as well as information obtained from the primary investigators (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<ALLOCATION MODIFIED="2015-02-18 15:21:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Sequence generation and allocation concealment</HEADING>
<P>Based on the information that we collected from the published reports and information from authors, we classed the allocation sequence generation and allocation concealment as low risk of bias in 10 trials (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). We classed the sequence generation and/or allocation concealment as unclear in the remaining six trials (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>). </P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2015-02-18 15:21:35 +0100" MODIFIED_BY="[Empty name]">
<P>Seven trials were open without blinding of participants or investigators (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>). We classed these trials as having a high risk of bias in the assessment of hepatic encephalopathy, adverse events, and quality of life. Nine trials were double blind with blinding of participants and personnel, and blinded outcome assessment. We classed them as low risk of performance and detection bias (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-02-18 15:21:39 +0100" MODIFIED_BY="[Empty name]">
<P>We classed four trials as having a high risk of attrition bias because they did not account for participants with missing outcomes (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>), and the remaining 12 trials as low risk of attrition bias (<LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>One trial published in abstract form did not report mortality (<LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>). We classed the trial as having a high risk of reporting bias. We had access to protocols for four trials (<LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). All four trials reported pre-defined outcomes including mortality and hepatic encephalopathy. We found that 15 trials reported the pre-defined outcomes (mortality and hepatic encephalopathy). We classed these 15 trials as having a low risk of reporting bias (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">For-profit funding</HEADING>
<P>Three trials received support from for-profit organisations in the form of interventions (<LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>). We classed these trials as high risk of bias for this domain. None of the remaining 14 trials received support from for-profit organisations (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>; <LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Cerra-1985" TYPE="STUDY">Cerra 1985</LINK>; <LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Michel-1985" TYPE="STUDY">Michel 1985</LINK>; <LINK REF="STD-Rossi_x002d_Fanelli-1986" TYPE="STUDY">Rossi-Fanelli 1986</LINK>; <LINK REF="STD-Strauss-1986" TYPE="STUDY">Strauss 1986</LINK>; <LINK REF="STD-Hwang-1988" TYPE="STUDY">Hwang 1988</LINK>; <LINK REF="STD-Marchesini-1990" TYPE="STUDY">Marchesini 1990</LINK>; <LINK REF="STD-Vilstrup-1990" TYPE="STUDY">Vilstrup 1990</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>; <LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>).</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-12-01 20:25:25 +0100" MODIFIED_BY="[Empty name]">
<P>We did not identify other biases for any of the included trials. </P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov">
<SUBSECTION>
<HEADING LEVEL="3">Mortality</HEADING>
<P>In total, 78 of 367 participants in the BCAA group versus 89 of 393 participants in the control group died (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Random-effects meta-analysis showed no difference between the groups (RR 0.88, 95% CI 0.69 to 1.11; 760 participants; 15 trials). The between-trial heterogeneity was unimportant (I<SUP>2</SUP> = 9%). The trial sequential analysis ignored the monitoring boundaries because the information in the cumulative meta-analysis was insufficient (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Accordingly, the analysis suggested that we do not have firm evidence to support or refute the effect of BCAA on mortality. Subgroup analyses of mortality found no difference between oral or intravenous BCAA (RR 0.90, 95% CI 0.50 to 1.63 for oral; RR 0.90, 95% CI 0.63 to 1.28; for intravenous; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), overt or minimal hepatic encephalopathy (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), different types of control interventions (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), or the type of data (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We did not perform a subgroup analysis to determine the effect of publication status because only trials published as full-paper articles reported mortality. The random-effects meta-regression found no predictors of heterogeneity for mortality (duration of therapy: P value = 0.37; dose of BCAA: P value = 0.57). In sensitivity analyses limited to trials with a low risk of bias, there was no effect of BCAA on mortality (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Mortality did not differ between the intervention groups in simple imputation with all losses to follow-up counted as treatment failures (RR 0.95, 95% CI 0.81 to 1.12) or in a worst-case scenario analysis with participants randomised to BCAA counted as treatment failures and controls as treatment successes (RR 0.96, 95% CI 0.76 to 1.20). There were no small-study effects (P value = 0.40). None of the participants died in the trial that included people with or without cirrhosis (<LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>), so exclusion of the trial had no influence on the overall result.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hepatic encephalopathy</HEADING>
<P>We gathered data on hepatic encephalopathy from all trials (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). Random-effects meta-analysis showed that BCAA was associated with a beneficial effect on hepatic encephalopathy compared with controls (RR 0.73, 95% CI 0.61 to 0.88; 827 participants). The between-trial heterogeneity was moderate (I<SUP>2</SUP> = 51%). In trial sequential analysis (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>), the cumulative Z-curve crossed the monitoring boundary before the required information size (also known as the diversity-adjusted required information size), which was 186 participants. When we repeated the analysis with a lower control group event rate and a lower RRR (adjusted for the potential risk of bias), the Z-curve crossed the monitoring boundary after inclusion of 546 participants before the required information size, which was 557 participants. Subgroup analysis found an effect of oral, but not intravenous BCAA (oral: RR 0.67, 95% CI 0.52 to 0.88; 430 participants; intravenous: RR 0.81, 95% CI 0.61 to 1.08; 397 participants; test for subgroup differences P value = 0.34; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). There were no differences between trials stratified in subgroups based on the type of hepatic encephalopathy (P value = 0.83; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), control groups (P value = 0.26; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>), published or re-calculated data (P value = 0.47; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>), or publication status (P value = 0.47; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). In sensitivity analyses, BCAA had a beneficial effect on hepatic encephalopathy in trials with a low risk of bias (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). There were no small-study effects (P value = 0.22). The benefit of BCAA on hepatic encephalopathy was confirmed in an analysis that counted all participants with missing outcomes as treatment failures (RR 1.32, 95% CI 1.15 to 1.51) and in a worst-case scenario analysis that counted participants randomised to BCAA as treatment failures and controls as treatment successes (RR 1.19, 95% CI 1.08 to 1.31). In one post-hoc analysis that excluded the trial on people with acute liver disease with or without cirrhosis (<LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>), BCAA had a beneficial effect on hepatic encephalopathy (RR 0.74, 95% CI 0.62 to 0.89; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). BCAA was also associated with a beneficial effect on mortality when excluding trials with a lactulose or neomycin control group (RR 0.76, 95% CI 0.63 to 0.92; 610 participants; 11 trials; I<SUP>2</SUP> = 52%; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>), but not when the analysis only included trials with a lactulose or neomycin control (RR 0.66, 95% CI 0.34 to 1.30; 195 participants; 4 trials; I<SUP>2</SUP> = 46%; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
<P>In univariable meta-regression analyses, we found no effect of the dose of BCAA (P value = 0.09), duration of treatment (P value = 0.21), or mode of administration (P value = 0.35). When combining the three potential predictors, multi-level meta-regression analysis showed no effect of the dose (P value = 0.50), mode of administration (P value = 0.82), or treatment duration (P value = 0.57). In univariable meta-regression analyses on participant characteristics, we reached a similar conclusion for the type of hepatic encephalopathy (P value = 0.07), mean age of included participants (P value = 0.50), proportion of men (P value = 0.94), proportion of people with alcoholic liver disease (P value = 0.09), and proportion of people with viral hepatitis (P value = 0.94). Likewise, we found no effect of the type of control group when analysed combined (placebo/no intervention, diet, lactulose, neomycin; P value = 0.75) or in separate assessments of placebo/no intervention (P value = 0.75), any diet (P value = 0.20), isonitrogenous isocaloric diet (P value = 0.80), neomycin (P value = 0.24), or lactulose (P value = 0.11). In multi-level meta-regression analyses with backwards elimination of all potential predictors, none remained in the model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>The trials did not report serious adverse events (apart from mortality). The most common non-serious adverse event was gastrointestinal discomfort (non-specific gastrointestinal symptoms that included both nausea and diarrhoea), which occurred in about 50 of 442 (11%) participants in the BCAA group and 11 of 503 (2%) participants randomised to control diets (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). BCAA increased the risk of nausea and diarrhoea in fixed-effect meta-analysis (RR 5.56, 95% CI 2.93 to 10.55), but not in random-effects meta-analysis (RR 3.39, 95% CI 0.70 to 16.46).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Three trials studying oral BCAA supplements evaluated the quality of life scores at baseline and end of treatment based on the 36-item Short Form (SF-36) questionnaire (<LINK REF="STD-Marchesini-2003" TYPE="STUDY">Marchesini 2003</LINK>; <LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>; <LINK REF="STD-Les-2011" TYPE="STUDY">Les 2011</LINK>). Due to the methods used to register scores, we were unable to combine the results in meta-analyses. All trials included people with cirrhosis. Some of the included participants did not have hepatic encephalopathy at baseline. When the analyses were limited to people with hepatic encephalopathy, none of the trials found beneficial or harmful effect of BCAA on the global SF-36 score or any of the subscales.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Nutritional outcomes</HEADING>
<P>The included trials did not perform comparable assessments of nutritional parameters. A meta-analysis of three trials with diet controls showed no difference in post-treatment albumin between the BCAA and control groups (MD 0.60, 95% CI -0.90 to 2.09; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). Analysis of one trial with a neomycin control group and two trials with isonitrogenous controls showed no difference between intervention groups regarding nitrogen balance (SMD 0.81, 95% CI 0.07 to 1.56; <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We have presented the key results on the outcomes mortality, hepatic encephalopathy, adverse events, and nutritional outcomes, and grading of the quality of the evidence in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. We showed the result of the primary meta-analysis for each outcome measure. As shown in the table, we only graded the quality of the evidence as 'high' for the outcome hepatic encephalopathy. We downgraded the evidence quality to 'moderate' for the remaining outcome measures, mainly due to imprecision.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-02-18 15:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>This review included 16 randomised clinical trials published from 1984 to 2011. Nearly all included participants had cirrhosis (97%). The trials compared BCAA versus placebo/no intervention, diets, lactulose, or neomycin. The results showed that BCAA have a beneficial effect on manifestations of hepatic encephalopathy. The between-trial heterogeneity was moderate, but none of the subgroup, sensitivity, or regression analyses was able to explain the heterogeneity. Different subgroup analyses showed a beneficial effect of oral, but not intravenous BCAA, and an effect of BCAA in trials on overt hepatic encephalopathy, but not on minimal hepatic encephalopathy. BCAA had a beneficial effect on hepatic encephalopathy when excluding trials with a lactulose or neomycin control group, but not in an analysis limited to trials with these two type of controls. However, the relatively small number of trials in the different subgroups limited the strength of the findings. Furthermore, none of the trials included several intervention arms comparing different types of BCAA or different control regimens. Additional analyses found that BCAA were associated with the gastrointestinal adverse events, diarrhoea and nausea, which occurred in about 1 in 10 people. We found no beneficial or detrimental effects of BCAA on the quality of life or nutritional outcomes.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-02-18 15:34:00 +0100" MODIFIED_BY="[Empty name]">
<P>Recent guidelines recommend routine treatment of people with overt hepatic encephalopathy (<LINK REF="REF-AASLD-and-EASL-guideline-2014a" TYPE="REFERENCE">AASLD and EASL guideline 2014a</LINK>; <LINK REF="REF-AASLD-and-EASL-guideline-2014b" TYPE="REFERENCE">AASLD and EASL guideline 2014b</LINK>). Oral BCAA are recommended as an alternative or add-on therapy to the first-line treatment, which is non-absorbable disaccharides. Our findings support the use of BCAA in clinical practice, but do not provide enough evidence to evaluate the benefit of BCAA compared with other interventions.</P>
<P>The cost effectiveness of interventions for the management of people with hepatic encephalopathy is important. Economic studies show that the total charges related to hepatic encephalopathy in the United States increased from $USD 4676.7 million in 2005 to $USD 7244.7 million in 2009 (<LINK REF="REF-Stepanova-2012" TYPE="REFERENCE">Stepanova 2012</LINK>). We did not assess the costs associated with hepatic encephalopathy, but our data may be used in future pharmacoeconomic reviews.</P>
<P>The present systematic review (as well as the previous version) included a heterogeneous group of trials. We decided to keep the broad scope of the review to identify common features within similar interventions. Grouping increases the external validity and consistency of the findings making it possible to assess the intervention effect across a wider range of settings and patient populations. The strategy also reduces chance results that can occur when analysing several smaller subgroups (<LINK REF="REF-Weir-2012" TYPE="REFERENCE">Weir 2012</LINK>). In theory, grouping makes it possible to make better judgements about the consistency of observed effects across trials and to look for differences between interventions, settings, and participant characteristics. We did not identify predictors of between-trial heterogeneity. None of the intervention or participant characteristics explained heterogeneity. However, we did not have enough data to exclude the possibility that there may be specific patient populations who benefit more or less from BCAA.</P>
<P>The diagnostic criteria used in individual trials varied. The variation largely reflected the differences that were occurred between the publication of the first trials in 1984 to (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Horst-1984" TYPE="STUDY">Horst 1984</LINK>) to the publication of the latest trial in 2005 (<LINK REF="STD-Muto-2005" TYPE="STUDY">Muto 2005</LINK>). Using a systematic approach to the assessment of hepatic encephalopathy was essential (<LINK REF="REF-Bajaj-2011" TYPE="REFERENCE">Bajaj 2011</LINK>). The included trials used methods such as the West Haven Criteria that are used in clinical practice (<LINK REF="REF-Ferenci-2002" TYPE="REFERENCE">Ferenci 2002</LINK>; <LINK REF="REF-Mullen-2007" TYPE="REFERENCE">Mullen 2007</LINK>; <LINK REF="REF-Bajaj-2008" TYPE="REFERENCE">Bajaj 2008</LINK>). This system grades symptoms from a clinically normal mental state (grade 0) over trivial signs such as shortened attention span to deep coma (grade 4). The clinically normal state includes people without overt hepatic encephalopathy and people with minimal hepatic encephalopathy that can be identified through psychometric testing such as the number connection test (<LINK REF="REF-Bajaj-2008" TYPE="REFERENCE">Bajaj 2008</LINK>; <LINK REF="REF-Bajaj-2011" TYPE="REFERENCE">Bajaj 2011</LINK>). In one cohort study of 217 people with cirrhosis, repeated evaluations showed that hepatic encephalopathy was not classed correctly in more than one third of people (<LINK REF="REF-Kircheis-2007" TYPE="REFERENCE">Kircheis 2007</LINK>). Therefore, thorough assessments are important. Likewise, careful evaluation is required to evaluate whether manifestations of hepatic encephalopathy is improved. Based on the differences in the diagnostic criteria, the assessment of this outcome measure varied in included trials. We chose to use the information and evaluation made by the original investigators. The extent to which manifestations improved will depend on the pre-defined criteria and the overall assessment is likely to involve some degree of subjective assessment. In spite of these limitations, the definition and assessment of outcomes reflect current clinical practice (<LINK REF="REF-Weissenborn-2013" TYPE="REFERENCE">Weissenborn 2013</LINK>).</P>
<P>One study found that BCAA supplementation increased ammonia levels in people with cirrhosis and healthy participants (<LINK REF="REF-Dam-2011" TYPE="REFERENCE">Dam 2011</LINK>). BCAA have a stimulatory effect on ammonia detoxification to glutamine and decreased concentrations in liver cirrhosis (<LINK REF="REF-Holecek-2013" TYPE="REFERENCE">Holecek 2013</LINK>). The reasons for the BCAA deficiency in cirrhosis include consumption in skeletal muscle for synthesis of glutamate. We were unable to determine the effect of BCAA in relation to the baseline BCAA concentrations or sarcopenia or ammonia levels. We found few data to determine the effect of BCAA on nutrition.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>When assessing the quality of the included trials, the internal as well as the external validity was important. Without adequate internal validity, the question of external validity becomes unimportant. Without adequate external validity, the trial may be clinically irrelevant in spite of an excellent basic methodology. In the assessment of internal validity, the control of bias associated with randomisation and blinding is important because it may lead to overestimated intervention effects (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>). When evaluating the effect of bias, we estimated that lack of blinding would not affect the assessment of mortality or laboratory parameters. In a study including 1973 randomised clinical trials from 234 meta-analyses (<LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>), authors found trials with inadequate or unclear (compared with adequate) sequence generation or allocation concealment overestimated intervention effects. The degree of bias was greatest for subjective outcomes and there was little evidence of bias for all-cause mortality (relative odds ratio 0.89, credibility interval 0.75 to 1.05). Lack of, or unclear, double blinding (compared with double blinding) was associated with a mean 13% exaggeration of intervention effects. Again, bias was detected in analyses of subjective outcomes and not for all-cause mortality. When we included the trials with a low risk of bias, we found no effect of BCAA on mortality, but a beneficial effect on hepatic encephalopathy when analysing bias domains separately or combined.</P>
<P>Some trials on BCAA used a cross-over design (<LINK REF="STD-Egberts-1985" TYPE="STUDY">Egberts 1985</LINK>; <LINK REF="STD-Plauth-1993" TYPE="STUDY">Plauth 1993</LINK>).The benefit of the design includes comparable control groups and increased statistical power. The use of the design in hepatic encephalopathy is debatable because the condition is a naturally fluctuating disease and because people may die during the first treatment period. Therefore, we chose to use only the first period of the cross-over trials in spite of the potential loss of information that this strategy entails (<LINK REF="REF-Lathyris-2007" TYPE="REFERENCE">Lathyris 2007</LINK>). The duration of therapy ranged from one to 104 weeks. Because we used the first treatment period from cross-over trials, the information that we included from the cross-over trials was based on a relatively shorter follow-up than trials using a parallel arm design. In our subgroup analyses, we found no difference between cross-over and parallel arm trials, and the duration of follow-up did not predict the treatment effect in our meta-regression. However, we cannot exclude the possibility that the duration of follow-up and trial design may be important.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-02-18 15:34:29 +0100" MODIFIED_BY="[Empty name]">
<P>The main potential bias in the review process is that we only had access to the published data from some of the included trials. We found no difference between the subgroups of trials with published summary data and trials for which we re-calculated outcomes for people with hepatic encephalopathy at baseline. On the one hand, this supports the strength of our findings. On the other hand, we cannot exclude that we would have been able to retrieve additional information if we had access to unpublished as well as published data from all trials. Two of the included trials were only published in abstract form (<LINK REF="STD-Fiaccadori-1984" TYPE="STUDY">Fiaccadori 1984</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>). In some trials, the complete results presented in the final full-text article differed from the initial analyses presented in abstract form (<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>). Access to the original patient data from trials published in abstract form may increase the strength of the analyses. Due to the risk of publication bias, we did not exclude unpublished trials and trials published in abstract form to avoid overestimation of intervention benefits.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-02-18 15:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>The previous version of this review included 11 randomised clinical trials with 556 participants (<LINK REF="REF-Als_x002d_Nielsen-2003" TYPE="REFERENCE">Als-Nielsen 2003</LINK>). This updated review included 16 trials with 827 participants. Both versions of the review included trials on oral or intravenous BCAA versus any control intervention. In both reviews, BCAA was not associated with reduced mortality. Likewise, both reviews found that BCAA was associated with a beneficial effect on hepatic encephalopathy. The previous review found that BCAA had a beneficial effect on improved manifestations of hepatic encephalopathy with an RR of 1.31 and an I<SUP>2</SUP> of 51%. The analysis included nine trials with a placebo/no intervention, diet, lactulose, or neomycin control group. In an analysis that included the same control groups, we included 16 trials and found that BCAA was associated with a beneficial effect on hepatic encephalopathy assessed based on the number of participants without improved manifestations with a RR of 0.73 and an I<SUP>2 </SUP>of 51%. The previous review concluded that the evidence was not convincing mainly because the subgroup analyses found no effect of BCAA on hepatic encephalopathy when analysing each domain separately. In the present review, an analysis that was limited to trials with a low risk of bias confirmed that BCAA has a beneficial effect on hepatic encephalopathy. Accordingly, the overall quantitative result of the two reviews concur, but only the updated review provided enough evidence from trials with an adequate control of bias.</P>
<P>One comprehensive Cochrane review from 2012 included randomised clinical trials on any type of nutritional support for any type of liver disease (<LINK REF="REF-Koretz-2012" TYPE="REFERENCE">Koretz 2012</LINK>). The review found no difference in mortality between nutritional therapy versus no nutritional therapy for liver disease in a medical setting. One meta-analysis of six trials (total 119 participants) found that nutritional supplements had a beneficial effect on resolution of hepatic encephalopathy. Two of the six trials evaluated BCAA (<LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>; <LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>). One of the trials included people with acute alcoholic hepatitis (<LINK REF="STD-Calvey-1985" TYPE="STUDY">Calvey 1985</LINK>). The trial found no differences between BCAA and control groups regarding mortality, hepatic encephalopathy, or nutritional parameters. The second trial included people with cirrhosis and found a beneficial effect of BCAA on improvement of hepatic encephalopathy (<LINK REF="STD-Hayashi-1991" TYPE="STUDY">Hayashi 1991</LINK>). The systematic review found that the effect of nutritional supplements on hepatic encephalopathy was more pronounced in subgroup analyses of trials with a high concentration of BCAA (<LINK REF="REF-Koretz-2012" TYPE="REFERENCE">Koretz 2012</LINK>). However, there was unclear control of bias and the total number of participants was small. Still the overall result concurred with our findings.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-02-18 15:34:59 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-02-18 15:34:50 +0100" MODIFIED_BY="[Empty name]">
<P>This review found that branched-chain amino acid (BCAA) was associated with a beneficial effect on hepatic encephalopathy associated with cirrhosis. The evidence suggested that BCAA should be considered in the management of people with hepatic encephalopathy. Adverse events were non-serious and mainly included gastrointestinal symptoms. There was no evidence to support or refute an effect of BCAA on mortality, quality of life, or nutritional outcomes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-02-18 15:34:59 +0100" MODIFIED_BY="[Empty name]">
<P>We need additional high-quality trials to evaluate the effect of BCAA combined with interventions that are used in clinical practice such as antibiotics and lactulose (<LINK REF="REF-AASLD-and-EASL-guideline-2014a" TYPE="REFERENCE">AASLD and EASL guideline 2014a</LINK>; <LINK REF="REF-AASLD-and-EASL-guideline-2014b" TYPE="REFERENCE">AASLD and EASL guideline 2014b</LINK>). We also need trials on people with minimal hepatic encephalopathy and trials with data on the quality of life and nutritional parameters. Additional research is also needed to evaluate if BCAA has a beneficial effect on hepatic encephalopathy in people with acute liver failure without cirrhosis and to identify if specific subgroups of people benefit from treatment with BCAA.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-05-10 11:38:26 +0200" MODIFIED_BY="Sarah  Klingenberg">
<P>We wish to thank all authors who provided additional data and information about their trials, and Dimitrinka Nikolova and Sarah Louise Klingenberg at the Cochrane Hepato-Biliary Group for their help.<BR/>
<BR/>Cochrane Review Group funding acknowledgement: The Danish State is the largest single funder of The Cochrane Hepato-Biliary Group through its investment in The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Denmark. Disclaimer: The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the Danish State or The Copenhagen Trial Unit.<BR/>
</P>
<P>Peer reviewers: Yukihiro Shimizu, Japan; Milan Holecek, Czech Republic.<BR/>Contact editor: Jian Ping Liu, China.<BR/>Deputy co-ordinating editor: Norberto Chavez-Tapia, Mexico.<BR/>Co-ordinating editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-05-17 14:38:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>None of the authors have any financial interests that may conflict with this review.</P>
<P>Lise Lotte Gluud had previously conducted Cochrane systematic reviews on the treatment of hepatic encephalopathy. As explained in the Cochrane Hepato-Biliary Group module (<LINK REF="REF-Gluud-2017" TYPE="REFERENCE">Gluud 2017</LINK>), this entails a risk of academic bias. Lise Lotte Gluud participated in scientific meetings in Denmark sponsored by Norgine.<BR/>Giulio Marchesini, Iñigo Les, and Hendrik Vilstrup had previously conducted clinical trials on BCAA, which also entails a risk of academic bias.<BR/>Niels Kristian Aagaard, Gitte Dam, and Mette Borre have no conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-05-17 14:37:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lise Lotte Gluud and Hendrik Vilstrup reviewed and updated the methods based on the previous review with incorporation of the revised guidelines described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>.</P>
<P>Lise Lotte Gluud, Gitte Dam, Iñigo Les, Giulio Marchesini, Mette Borre, Niels Kristian Aagaard, and Hendrik Vilstrup approved of the final version of the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-02-18 15:36:07 +0100" MODIFIED_BY="[Empty name]">
<P>The methods of the review were updated to reflect the current guidelines described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> and the Cochrane Hepato-Biliary Group Module. Based on the most recent recommendations, the primary outcomes were mortality, hepatic encephalopathy, and adverse events. We also updated the assessment of bias control and statistical analyses. The previous review included published data from trials with a high proportion of people with hepatic encephalopathy at baseline. We were able to retrieve data that allowed re-calculation of outcomes and were, therefore, able to limit our analyses to people with hepatic encephalopathy. Accordingly, we did not evaluate the proportion of people with hepatic encephalopathy in our trial selection criteria.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-10-02 17:23:01 +0200" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-05-17 13:40:36 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2017-05-10 12:29:17 +0200" MODIFIED_BY="Sarah  Klingenberg">
<INCLUDED_STUDIES MODIFIED="2017-05-10 12:27:49 +0200" MODIFIED_BY="Sarah  Klingenberg">
<STUDY DATA_SOURCE="PUB" ID="STD-Calvey-1985" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Calvey 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-07-11 16:38:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Calvey H, Davis M, Williams R</AU>
<TI>Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis</TI>
<SO>Journal of Hepatology</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>141-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672562"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-21 14:08:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calvey H, Davis M, Williams R</AU>
<TI>Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis</TI>
<SO>Clinical Nutrition</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>63-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Williams R, Calvey H, Davis M</AU>
<TI>Controlled trial of nutritional supplementation in acute alcoholic hepatitis</TI>
<SO>Metabolism and Nutrition in Liver Disease</SO>
<YR>1985</YR>
<PG>361-8</PG>
<ED>Holm EKH</ED>
<PB>MTP Press, Ltd</PB>
<CY>Lancaster, UK</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672564"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672561"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cerra-1985" MODIFIED="2017-05-10 12:19:37 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Cerra 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-03-21 14:22:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cerra FB, Cheung NK, Fischer JE, Kaplowitz N, Schiff E-R, Dienstag JL, et al</AU>
<TI>Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial</TI>
<SO>JPEN. Journal of Parenteral and Enteral Nutrition</SO>
<YR>1985</YR>
<VL>9</VL>
<PG>288-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672566"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 12:19:37 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerra FB, Cheung NK, Fischer JE, Kaplowitz N, Schiff ER, Dienstag JL, et al</AU>
<TI>A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE)</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1982</YR>
<VL>2</VL>
<PG>699</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672567"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-06 15:07:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerra FB, McMillen M, Angelico R, Cline B, Lyons J, Faulkenbach L, et al</AU>
<TI>Cirrhosis, encephalopathy, and improved results with metabolic support</TI>
<SO>Surgery</SO>
<YR>1983</YR>
<VL>94</VL>
<PG>612-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672568"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Cerra FB</AU>
<TI>Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial [personal communication]</TI>
<SO>Correspondence with authors</SO>
<YR>September 2002</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672569"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672565"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egberts-1985" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Egberts 1985" YEAR="1986">
<REFERENCE MODIFIED="2014-03-21 14:24:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egberts EH, Hamster W, Schomeerus H, Jürgens P</AU>
<TI>Effect of branched chain amino acids on latent porto-systemic-encephalopathy (PSE)</TI>
<SO>JPEN. Journal of Parenteral and Enteral Nutrition</SO>
<YR>1981</YR>
<VL>5</VL>
<PG>5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672571"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Egberts EH, Schomeerus H, Hamster W, Jürgens P</AU>
<TI>Effective treatment of latens porto-systemic encephalopathy with oral branched chain amino acids</TI>
<SO>Hepatic Encephalopathy in Chronic Liver Failure</SO>
<YR>1984</YR>
<PG>351-7</PG>
<ED>Capocaccia L, Fischer JE, Rossi-Fanelli F</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672572"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-21 14:24:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egberts EH, Schomerus H, Hamster W, Jürgens P</AU>
<TI>Branched-chain amino acids in the treatment of latent porto-systemic encephalopathy. A placebo-controlled double-blind cross-over study</TI>
<TO>Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind-cross-over-studie</TO>
<SO>Zeitschrift für Ernährungswissenschaft</SO>
<YR>1986</YR>
<VL>25</VL>
<PG>9-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672573"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-06 15:07:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Egberts EH, Schomerus H, Hamster W, Jurgens P</AU>
<TI>Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double-blind placebo-controlled crossover study</TI>
<SO>Gastroenterology</SO>
<YR>1985</YR>
<VL>88</VL>
<PG>887-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672574"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-04 15:19:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamster W, Egberts EH, Hamster H</AU>
<TI>Treatment with branched-chain amino acids and effect on psycho-physical capacity functions in latent porto-systemic encephalopathy</TI>
<TO>Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie</TO>
<SO>Arzneimittelforschung</SO>
<YR>1982</YR>
<VL>32</VL>
<PG>901-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672575"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672570"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Fiaccadori-1984" MODIFIED="2015-02-19 09:08:13 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Fiaccadori 1984" YEAR="">
<REFERENCE MODIFIED="2014-04-04 15:19:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Fiaccadori F, Ghinelli F, Pedretti G, Mancia D</AU>
<TI>Mental state course and biochemical findings in HE treated by BCAA-enriched mixtures</TI>
<SO>Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium</SO>
<YR>1985</YR>
<PG>281-5</PG>
<ED>Holm E, Kasper H</ED>
<PB>MTP Press</PB>
<CY>Lancaster</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672577"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-04 15:20:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Fiaccadori F, Ghinelli F, Pedretti G, Pelosi G, Sacchini D, Zeneroli ML, et al</AU>
<TI>Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial</TI>
<SO>Hepatic Encephalopathy in Chronic Liver Failure</SO>
<YR>1984</YR>
<PG>323-33</PG>
<ED>Capocaccia L, Fischer JE, Rossi-Fanelli F</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672578"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-11 14:49:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fiaccadori F, Ghinelli F, Pedretti G</AU>
<TI>Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial</TI>
<SO>Italian Journal of Gastroenterology</SO>
<YR>1985</YR>
<VL>17</VL>
<PG>5-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672579"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiaccadori F, Ghinelli F, Pelosi G, Sacchini D, Vaona G, Zeneroli ML, et al</AU>
<TI>Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report)</TI>
<SO>La Ricerca in Clinica e in Laboratorio</SO>
<YR>1980</YR>
<VL>10</VL>
<PG>411-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672580"/><IDENTIFIER TYPE="MEDLINE" VALUE="81102770"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="OTHER">
<AU>Fiaccadori F</AU>
<TI>Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial</TI>
<SO>Italian Journal of Gastroenterology (additional information from author November 2012)</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672581"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672576"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayashi-1991" MODIFIED="2015-01-20 20:38:53 +0100" MODIFIED_BY="[Empty name]" NAME="Hayashi 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-03-09 18:30:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayashi S, Aoyagi Y, Fujiwara K, Oka H, Oda T</AU>
<TI>A randomized controlled trial of branched-chain amino acid (BCAA)-enriched elemental diet (ED-H) for hepatic encephalopathy</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>191</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672583"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672582"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horst-1984" MODIFIED="2017-05-10 12:22:13 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Horst 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-05-10 12:22:02 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horst D, Grace N, Conn HO, Schiff E, Schenker S, Viteri A, et al</AU>
<TI>A double-blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal-systemic encephalopathy (PSE) [IASL abstract]</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1982</YR>
<VL>2</VL>
<PG>184</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672585"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 12:22:13 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horst D, Grace ND, Conn HO, Schiff E, Schenker S, Viteri A, et al</AU>
<TI>Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>279-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672586"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672584"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hwang-1988" MODIFIED="2014-04-02 14:03:34 +0200" MODIFIED_BY="[Empty name]" NAME="Hwang 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-07-11 14:49:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hwang SJ, Chan CY, Wu JC, Lee SD, Huan YS, Tsai YT, et al</AU>
<TI>A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid-enriched amino acid solution in the treatment of patients with hepatic encephalopathy</TI>
<SO>Chinese Journal of Gastroenterology</SO>
<YR>1988</YR>
<VL>5</VL>
<PG>185-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672588"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672587"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Les-2011" MODIFIED="2015-01-20 21:31:14 +0100" MODIFIED_BY="[Empty name]" NAME="Les 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-01-20 21:29:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, et al</AU>
<TI>Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>106</VL>
<PG>1081-8</PG>
<IDENTIFIERS MODIFIED="2011-03-09 18:31:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672590"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-09 19:16:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672589"/><IDENTIFIER MODIFIED="2011-03-09 19:16:20 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00955500"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchesini-1990" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Marchesini 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bianchi GP, Marchesini G, Zoli M, Abbiati R, Ferrario E, Fabbri A, et al</AU>
<TI>Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels</TI>
<SO>Hepato-gastroenterology</SO>
<YR>1992</YR>
<VL>39</VL>
<PG>443-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672592"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-21 14:54:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al</AU>
<TI>Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<PG>1792-801</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672593"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al</AU>
<TI>Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein controlled trial. The Italian Multicenter Study Group</TI>
<SO>Journal of Hepatology</SO>
<YR>1990</YR>
<VL>11</VL>
<PG>92-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672594"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672591"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Marchesini-2003" MODIFIED="2015-01-20 21:31:32 +0100" MODIFIED_BY="[Empty name]" NAME="Marchesini 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-03-21 14:55:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al</AU>
<TI>Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<PG>1980-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672596"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672595"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michel-1985" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Michel 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H</AU>
<TI>Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients</TI>
<SO>Liver</SO>
<YR>1985</YR>
<VL>5</VL>
<PG>282-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672598"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-21 15:00:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Michel H, Pomier-Layrargues G, Aubin JP, Bories P, Mirouze D, Bellet-Herman H</AU>
<TI>Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients</TI>
<SO>Hepatic Encephalopathy in Chronic Liver Failure</SO>
<YR>1984</YR>
<PG>301-10</PG>
<ED>Capocaccia L, Fischer JE, Rossi-Fanelli F</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672599"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-11 14:50:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michel H, Pomier-Layrargues G, Duhamel O, Lacombe B, Cuilleret G, Bellet-Hermann H</AU>
<TI>Intravenous infusion of ordinary and modified amino-acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients)</TI>
<SO>Gastroenterology</SO>
<YR>1980</YR>
<VL>79</VL>
<PG>1038</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672600"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-21 15:00:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pomier-Layrargues G, Duhamel O, Lacombe B, Cuilleret G, Bellet H, Michel H</AU>
<TI>Intravenous infusion of ordinary and modified amino-acid solutions in the management of hepatic encephalopathy</TI>
<SO>Liver</SO>
<YR>1981</YR>
<VL>1</VL>
<PG>140</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672601"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672597"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Muto-2005" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Muto 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="OTHER">
<AU>Horie-Takashi I</AU>
<TI>Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>705-13 (additional information and data received November 2011)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672603"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-21 15:01:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al</AU>
<TI>Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>705-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672604"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-06 15:09:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato S, Watanabe A, Muto Y, Suzuki K, Kato A, Moriwaki H, et al</AU>
<TI>Clinical comparison of branched-chain amino acid (l-Leucine, l-Isoleucine, l-Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study)</TI>
<SO>Hepatology Research</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>232-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672605"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672602"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plauth-1993" MODIFIED="2017-05-10 12:26:06 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Plauth 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-05-10 12:26:06 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plauth M, Egberts E-H, Hamster W, Török M, Müller P, Brand O, et al</AU>
<TI>Long-term treatment with branched-chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1992</YR>
<VL>69</VL>
<PG>126</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672607"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-21 15:02:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Plauth M, Egberts EH, Hamster W, Török M, Müller PH, Brand O, et al</AU>
<TI>Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-crossover study</TI>
<SO>Journal of Hepatology</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>308-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672608"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672606"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossi_x002d_Fanelli-1986" MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Rossi-Fanelli 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Riggio O, Cangiano C, Cascino A, Merli M, Stortoni M, Rossi-Fanelli F, et al</AU>
<TI>Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto-caval anastomosis</TI>
<SO>Hepatic Encephalopathy in Chronic Liver Failure</SO>
<YR>1984</YR>
<PG>183-92</PG>
<ED>Associazione Italiana per Lo Studio del Fegato. Congress</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672610"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rossi-Fanelli F, Cangiano C, Capocaccia L, Cascino A, Ceci F, Muscaritoli M, et al</AU>
<TI>Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences</TI>
<SO>Gut</SO>
<YR>1986</YR>
<VL>27</VL>
<PG>111-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672611"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Rossi-Fanelli F, Cangiano C, Cascino A, Merli M, Riggio O, Stortoni M, et al</AU>
<TI>Branched-chain amino acids in the treatment of severe hepatic encephalopathy</TI>
<SO>Hepatic Encephalopathy in Chronic Liver Failure</SO>
<YR>1984</YR>
<PG>335-44</PG>
<ED>Capocaccia L, Fischer JE, Rossi-Fanelli F</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672612"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossi-Fanelli F, Riggio O, Cangiano C, Cascino A, De Conciliis D, Merli M, et al</AU>
<TI>Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1982</YR>
<VL>27</VL>
<PG>929-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672613"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672609"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Strauss-1986" MODIFIED="2017-05-10 12:27:38 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Strauss 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-07-11 16:44:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Strauss E, Cartapatti Da Silva E, Lacet CM, Capacci MLL, Bernardini AP</AU>
<TI>Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin</TI>
<SO>Nutritional Support Services</SO>
<YR>1986</YR>
<VL>6</VL>
<PG>18-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672615"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 12:27:38 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strauss E, Santos WR, Da Silva EC, Lacet CM, Capacci LL, Bernardini AP</AU>
<TI>A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched-chain amino-acid solution compared to neomycin in hepatic encephalopathy</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>862</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672616"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672614"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vilstrup-1990" MODIFIED="2017-05-10 12:27:49 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Vilstrup 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-07-11 14:50:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gluud C, Dejgaard A, Hardt F, Kristensen M, Køhler O, Melgaard B, et al</AU>
<TI>Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1983</YR>
<VL>18</VL>
<PG>19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672618"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 12:27:49 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vilstrup H, Gluud C, Hardt F, Kristensen M, Køhler O, Melgaard B, et al</AU>
<TI>Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 patients with cirrhosis</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1990</YR>
<VL>10</VL>
<PG>291-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672619"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vilstrup H, Gluud C, Hardt F, Kristensen M, Melgaard B, Køhler O, et al</AU>
<TI>Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver</TI>
<SO>Journal of Hepatology</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>S347</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672620"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672617"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-05-10 12:28:25 +0200" MODIFIED_BY="Sarah  Klingenberg">
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksson-1982" MODIFIED="2008-05-17 19:20:16 +0200" MODIFIED_BY="[Empty name]" NAME="Eriksson 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-05-17 19:20:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson LS, Persson A, Wahren J</AU>
<TI>Branched-chain amino acids in the treatment of chronic hepatic encephalopathy</TI>
<SO>Gut</SO>
<YR>1982</YR>
<VL>23</VL>
<PG>801-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672622"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672621"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayashi-2007" MODIFIED="2015-01-06 15:12:09 +0100" MODIFIED_BY="[Empty name]" NAME="Hayashi 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-01-06 15:12:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayashi M, Ikezawa K, Ono A, Okabayashi S, Hayashi Y, Shimizu S, et al</AU>
<TI>Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis</TI>
<SO>Hepatology Research</SO>
<YR>2007</YR>
<VL>37</VL>
<PG>615-19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672624"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672623"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malaguarnera-2009" MODIFIED="2014-03-21 15:32:45 +0100" MODIFIED_BY="[Empty name]" NAME="Malaguarnera 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-21 15:32:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malaguarnera M, Risino C, Cammalleri L, Malaguarnera L, Astuto M, Vecchio I, et al</AU>
<TI>Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2009</YR>
<VL>21</VL>
<PG>762-70</PG>
<IDENTIFIERS MODIFIED="2011-03-09 19:04:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672626"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672625"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Keefe-1987" MODIFIED="2015-02-16 22:08:58 +0100" MODIFIED_BY="Anne Lawson" NAME="O'Keefe 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-03-21 15:33:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Keefe SJ, Ogden J, Dicker J</AU>
<TI>Enteral and parenteral branched chain amino acid-supplemented nutritional support in patients with encephalopathy due to alcoholic liver disease</TI>
<SO>JPEN. Journal of Parenteral and Enteral Nutrition</SO>
<YR>1987</YR>
<VL>11</VL>
<PG>447-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672628"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672627"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wahren-1983" MODIFIED="2017-05-10 12:28:25 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Wahren 1983" YEAR="1983">
<REFERENCE MODIFIED="2017-05-10 12:28:25 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahren J, Denis J, Desurmont P, Eriksson LS, Escoffier JM, Gauthier AP, et al</AU>
<TI>Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>475-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672630"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672629"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-1982" MODIFIED="2011-03-09 19:14:24 +0100" MODIFIED_BY="[Empty name]" NAME="Walker 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-03-09 19:14:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker S, Gotz R, Czygan P, Stiehl A, Lanzinger G, Sieg A, et al</AU>
<TI>Oral keto analogs of branched-chain amino acids in hyperammonemia in patients with cirrhosis of the liver. A double-blind crossover study</TI>
<SO>Digestion</SO>
<YR>1982</YR>
<VL>24</VL>
<PG>105-11</PG>
<IDENTIFIERS MODIFIED="2011-03-09 19:14:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672632"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672631"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-12-03 15:03:43 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2017-05-10 12:29:17 +0200" MODIFIED_BY="Sarah  Klingenberg">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ACTRN12610001021066" MODIFIED="2017-05-10 12:29:17 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="ACTRN12610001021066" YEAR="2010">
<REFERENCE MODIFIED="2017-05-10 12:29:17 +0200" MODIFIED_BY="Sarah  Klingenberg" PRIMARY="NO" TYPE="OTHER">
<TI>The effects of supplementation with synbiotics, branched chain amino acids on levels of hepatic encephalopathy in patients with cirrhosis</TI>
<SO>www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610001021066</SO>
<YR>(accessed 10 May 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2672634"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-24 11:05:26 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2672633"/><IDENTIFIER MODIFIED="2013-07-24 11:05:26 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12610001021066"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-05-10 12:53:06 +0200" MODIFIED_BY="Sarah  Klingenberg">
<ADDITIONAL_REFERENCES MODIFIED="2017-05-10 12:53:06 +0200" MODIFIED_BY="Sarah  Klingenberg">
<REFERENCE ID="REF-AASLD-and-EASL-guideline-2014a" MODIFIED="2017-05-10 12:38:27 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="AASLD and EASL guideline 2014a" TYPE="JOURNAL_ARTICLE">
<AU>Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al</AU>
<TI>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2014</YR>
<VL>60</VL>
<PG>715-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AASLD-and-EASL-guideline-2014b" MODIFIED="2014-10-02 17:18:13 +0200" MODIFIED_BY="[Empty name]" NAME="AASLD and EASL guideline 2014b" TYPE="JOURNAL_ARTICLE">
<AU>American Association for the Study of Liver Diseases, European Association for the Study of the Liver</AU>
<TI>Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases</TI>
<SO>Journal of Hepatology</SO>
<YR>2014</YR>
<VL>61</VL>
<PG>642-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amodio-2008" MODIFIED="2014-03-21 15:39:09 +0100" MODIFIED_BY="[Empty name]" NAME="Amodio 2008" TYPE="JOURNAL_ARTICLE">
<AU>Amodio P, Campagna F, Olianas S, Iannizzi P, Mapelli D, Penzo M, et al</AU>
<TI>Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study</TI>
<SO>Journal of Hepatology</SO>
<YR>2008</YR>
<VL>49</VL>
<NO>3</NO>
<PG>346-53</PG>
<IDENTIFIERS MODIFIED="2011-03-12 02:41:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18602716"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Amodio-2014" MODIFIED="2015-01-06 15:18:20 +0100" MODIFIED_BY="[Empty name]" NAME="Amodio 2014" TYPE="JOURNAL_ARTICLE">
<AU>Amodio P, Canesso F, Montagnese S</AU>
<TI>Dietary management of hepatic encephalopathy revisited</TI>
<SO>Current Opinion in Clinical Nutrition and Metabolic Care</SO>
<YR>2014</YR>
<VL>17</VL>
<NO>5</NO>
<PG>448-52</PG>
<IDENTIFIERS MODIFIED="2014-11-11 08:32:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25025262"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2008" MODIFIED="2014-03-21 15:39:33 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS</AU>
<TI>Minimal encephalopathy matters in daily life</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>23</NO>
<PG>3609-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2010" MODIFIED="2014-12-05 12:20:54 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS</AU>
<TI>Review article: the modern management of hepatic encephalopathy</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>5</NO>
<PG>537-47</PG>
<IDENTIFIERS MODIFIED="2014-11-11 12:54:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20002027"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2011" MODIFIED="2014-03-24 17:27:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Bajaj 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al</AU>
<TI>Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>7</NO>
<PG>739-47</PG>
<IDENTIFIERS MODIFIED="2011-03-12 02:44:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21306407"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bak-2006" MODIFIED="2009-03-08 19:07:34 +0100" MODIFIED_BY="[Empty name]" NAME="Bak 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bak LK, Schousboe A, Waagepetersen HS</AU>
<TI>The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer</TI>
<SO>Journal of Neurochemistry</SO>
<YR>2006</YR>
<VL>98</VL>
<PG>641-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blei-2001" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Blei 2001" TYPE="JOURNAL_ARTICLE">
<AU>Blei AT, Córdoba J, Practice Parameters Committee of the American College of Gastroenterology</AU>
<TI>Hepatic encephalopathy</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>1986-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-C_x00f3_rdoba-2004" MODIFIED="2015-02-17 08:35:09 +0100" MODIFIED_BY="Anne Lawson" NAME="Córdoba 2004" TYPE="JOURNAL_ARTICLE">
<AU>Córdoba J, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F, et al</AU>
<TI>Normal protein diet for episodic hepatic encephalopathy: results of a randomized study</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>41</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dam-2011" MODIFIED="2014-12-05 12:21:52 +0100" MODIFIED_BY="[Empty name]" NAME="Dam 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dam G, Keiding S, Munk OL, Ott P, Buhl M, Vilstrup H, et al</AU>
<TI>Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects</TI>
<SO>American Journal of Physiology. Gastrointestinal and Liver Physiology</SO>
<YR>2011</YR>
<VL>301</VL>
<NO>2</NO>
<PG>G269-77</PG>
<IDENTIFIERS MODIFIED="2014-06-05 14:18:22 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21636533"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2014-12-05 12:22:03 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS MODIFIED="2014-06-05 09:42:06 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="9310563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferenci-2002" MODIFIED="2017-05-10 12:41:02 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Ferenci 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT</AU>
<TI>Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>3</NO>
<PG>716-21</PG>
<IDENTIFIERS MODIFIED="2011-03-12 02:36:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="11870389"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fichet-2009" MODIFIED="2014-03-21 15:41:00 +0100" MODIFIED_BY="[Empty name]" NAME="Fichet 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fichet J, Mercier E, Genée O, Garot D, Legras A, Dequin PF, et al</AU>
<TI>Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy</TI>
<SO>Journal of Critical Care</SO>
<YR>2009</YR>
<VL>24</VL>
<PG>364-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Martinez-2011" MODIFIED="2014-03-21 15:42:02 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Martinez 2011" TYPE="JOURNAL_ARTICLE">
<AU>García-Martínez R, Córdoba J</AU>
<TI>Acute-on-chronic liver failure: the brain</TI>
<SO>Current Opinion in Critical Care</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>2</NO>
<PG>177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-1991" MODIFIED="2017-05-10 12:41:20 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Gluud 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gluud C</AU>
<TI>Branched-chain amino acids for hepatic encephalopathy?</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>4</NO>
<PG>812-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2010" MODIFIED="2014-03-21 15:42:17 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gluud LL, Langholz E, Krag A</AU>
<TI>Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>7</NO>
<PG>859-71</PG>
<IDENTIFIERS MODIFIED="2013-07-30 14:41:15 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20839387"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2013a" MODIFIED="2015-02-17 08:35:49 +0100" MODIFIED_BY="Anne Lawson" NAME="Gluud 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, et al</AU>
<TI>Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials</TI>
<SO>Journal of Nutrition</SO>
<YR>2013</YR>
<VL>143</VL>
<PG>1263-8</PG>
<IDENTIFIERS MODIFIED="2013-07-11 15:28:46 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23739310"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2013b" MODIFIED="2015-02-17 08:35:43 +0100" MODIFIED_BY="Anne Lawson" NAME="Gluud 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, et al</AU>
<TI>Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?</TI>
<SO>Metabolic Brain Disease</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>2</NO>
<PG>221-5</PG>
<IDENTIFIERS MODIFIED="2013-07-11 15:28:46 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23275147"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2017" MODIFIED="2017-05-10 12:46:21 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Gluud 2017" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2017, Issue 4. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2017-05-10 12:47:03 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Grade Working Group 2004-2007</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guerit-2009" MODIFIED="2014-03-24 17:27:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guerit 2009" TYPE="JOURNAL_ARTICLE">
<AU>Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, et al</AU>
<TI>Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>6</NO>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2013-07-11 14:55:42 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="19638107"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2014-12-05 12:24:19 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2014-06-05 10:02:32 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18436948"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2014-06-05 09:39:12 +0200" MODIFIED_BY="[Empty name]" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="16345038"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2014-04-04 15:27:23 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, White IR, Wood AM</AU>
<TI>Imputation methods for missing outcome data in meta-analysis of clinical trials</TI>
<SO>Clinical Trials</SO>
<YR>2008</YR>
<VL>5</VL>
<PG>225-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2015-09-08 12:46:28 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Whitehead A, Simmonds M</AU>
<TI>Sequential methods for random-effects meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>9</NO>
<PG>903-21</PG>
<IDENTIFIERS MODIFIED="2011-04-10 18:30:46 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21472757"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holecek-2010" MODIFIED="2014-12-05 12:24:50 +0100" MODIFIED_BY="[Empty name]" NAME="Holecek 2010" TYPE="JOURNAL_ARTICLE">
<AU>Holecek M</AU>
<TI>Three targets of branched-chain amino acid supplementation in the treatment of liver disease</TI>
<SO>Nutrition (Burbank, Los Angeles County, Calif.)</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>5</NO>
<PG>482-90</PG>
<IDENTIFIERS MODIFIED="2011-03-09 15:50:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20071143"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holecek-2011" MODIFIED="2014-12-05 12:24:56 +0100" MODIFIED_BY="[Empty name]" NAME="Holecek 2011" TYPE="JOURNAL_ARTICLE">
<AU>Holecek M, Kandar R, Sispera L, Kovarik M</AU>
<TI>Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscle</TI>
<SO>Amino Acids</SO>
<YR>2011</YR>
<VL>40</VL>
<NO>2</NO>
<PG>575-84</PG>
<IDENTIFIERS MODIFIED="2014-06-05 14:08:37 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20614225"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holecek-2013" MODIFIED="2014-06-05 14:23:08 +0200" MODIFIED_BY="[Empty name]" NAME="Holecek 2013" TYPE="JOURNAL_ARTICLE">
<AU>Holecek M</AU>
<TI>Branched-chain amino acids and ammonia metabolism in liver disease: therapeutic implications</TI>
<SO>Nutrition (Burbank, Los Angeles County, Calif.)</SO>
<YR>2013</YR>
<VL>29</VL>
<NO>10</NO>
<PG>1186-91</PG>
<IDENTIFIERS MODIFIED="2014-06-05 14:23:05 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23756281"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holecek-2014" MODIFIED="2014-12-05 12:25:11 +0100" MODIFIED_BY="[Empty name]" NAME="Holecek 2014" TYPE="JOURNAL_ARTICLE">
<AU>Holecek M</AU>
<TI>Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives</TI>
<SO>Metabolic Brain Disease</SO>
<YR>2014</YR>
<VL>29</VL>
<NO>1</NO>
<PG>9-17</PG>
<IDENTIFIERS MODIFIED="2014-11-05 19:39:07 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23996300"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ICH-GCP-1997" MODIFIED="2017-05-10 12:49:48 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="ICH GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>Philadelphia (PA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kachaamy-2011" MODIFIED="2011-03-09 15:35:05 +0100" MODIFIED_BY="[Empty name]" NAME="Kachaamy 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kachaamy T, Bajaj JS</AU>
<TI>Diet and cognition in chronic liver disease</TI>
<SO>Current Opinion Gastroenterology</SO>
<YR>2011</YR>
<VL>27</VL>
<PG>174-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kawaguchi-2013" MODIFIED="2014-12-05 12:26:40 +0100" MODIFIED_BY="[Empty name]" NAME="Kawaguchi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kawaguchi T, Taniguchi E, Sata M</AU>
<TI>Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis</TI>
<SO>Nutrition in Clinical Practice</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>5</NO>
<PG>580-8</PG>
<IDENTIFIERS MODIFIED="2014-11-05 19:51:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23945292"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kircheis-2007" MODIFIED="2014-03-21 15:51:29 +0100" MODIFIED_BY="[Empty name]" NAME="Kircheis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kircheis G, Fleig WE, Gortelmeyer R, Grafe S, Haussinger D</AU>
<TI>Assessment of low-grade hepatic encephalopathy: a critical analysis</TI>
<SO>Journal of Hepatology</SO>
<YR>2007</YR>
<VL>47</VL>
<NO>5</NO>
<PG>642-50</PG>
<IDENTIFIERS MODIFIED="2011-03-12 02:40:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17869373"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koretz-2012" MODIFIED="2014-03-21 15:53:36 +0100" MODIFIED_BY="[Empty name]" NAME="Koretz 2012" TYPE="COCHRANE_REVIEW">
<AU>Koretz RL, Avenell A, Lipman TO</AU>
<TI>Nutritional support for liver disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2014-03-21 15:53:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-03-21 15:53:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008344.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="22592729"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lathyris-2007" MODIFIED="2014-03-21 15:53:54 +0100" MODIFIED_BY="[Empty name]" NAME="Lathyris 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lathyris DN, Trikalinos TA, Ioannidis JP</AU>
<TI>Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>2</NO>
<PG>422-30</PG>
<IDENTIFIERS MODIFIED="2013-07-30 13:53:56 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17301102"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MECIR-2014" MODIFIED="2015-08-25 15:23:42 +0200" MODIFIED_BY="[Empty name]" NAME="MECIR 2014" TYPE="OTHER">
<TI>Methodological Expectations of Cochrane Intervention Reviews (MECIR)</TI>
<SO>www.editorial-unit.cochrane.org/mecir</SO>
<YR>(accessed 25 August 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metcalfe-2014" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Metcalfe 2014" TYPE="JOURNAL_ARTICLE">
<AU>Metcalfe EL, Avenell A, Fraser A</AU>
<TI>Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: systematic review</TI>
<SO>Clinical Nutrition (Edinburgh, Scotland)</SO>
<YR>2014</YR>
<VL>33</VL>
<NO>6</NO>
<PG>958-65</PG>
<IDENTIFIERS MODIFIED="2014-11-11 08:39:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24656171"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mullen-2007" MODIFIED="2014-03-21 15:54:05 +0100" MODIFIED_BY="[Empty name]" NAME="Mullen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mullen KD</AU>
<TI>Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>11-6</PG>
<IDENTIFIERS MODIFIED="2011-03-12 02:38:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17295847"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Naylor-1989" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Naylor 1989" TYPE="JOURNAL_ARTICLE">
<AU>Naylor CD, O'Rourke D, Detsky AS, Baker JP</AU>
<TI>Parenteral nutrition with branched-amino acids in hepatic encephalopathy. A meta-analysis</TI>
<SO>Gastroenterology</SO>
<YR>1989</YR>
<VL>97</VL>
<PG>1033-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olde-2002" MODIFIED="2017-05-10 12:50:32 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Olde 2002" TYPE="JOURNAL_ARTICLE">
<AU>Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB</AU>
<TI>Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>5</NO>
<PG>1163-71</PG>
<IDENTIFIERS MODIFIED="2011-03-09 16:00:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="12395326"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rakoski-2012" MODIFIED="2014-11-11 10:02:54 +0100" MODIFIED_BY="[Empty name]" NAME="Rakoski 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rakoski MO, McCammon RJ, Piette JD, Iwashyna TJ, Marrero JA, Lok AS, et al</AU>
<TI>Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2012</YR>
<VL>55</VL>
<NO>1</NO>
<PG>184-91</PG>
<IDENTIFIERS MODIFIED="2014-11-11 10:02:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21858847"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Randolph-2009" MODIFIED="2014-03-24 17:27:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Randolph 2009" TYPE="JOURNAL_ARTICLE">
<AU>Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, et al</AU>
<TI>Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>5</NO>
<PG>629-35</PG>
<IDENTIFIERS MODIFIED="2013-07-11 14:55:42 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="19302444"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-08-25 15:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roman-2014" MODIFIED="2014-12-05 12:29:11 +0100" MODIFIED_BY="[Empty name]" NAME="Roman 2014" TYPE="JOURNAL_ARTICLE">
<AU>Roman E, Torrades MT, Nadal MJ, Cardenas G, Nieto JC, Vidal S, et al</AU>
<TI>Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2014</YR>
<VL>59</VL>
<NO>8</NO>
<PG>1966-75</PG>
<IDENTIFIERS MODIFIED="2014-11-05 18:07:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24599772"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2014-03-21 13:28:30 +0100" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012" MODIFIED="2014-03-24 17:27:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Savovic 2012" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS MODIFIED="2013-07-30 13:41:57 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22945832"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stata-13" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Stata 13" TYPE="COMPUTER_PROGRAM">
<TI>Stata 13</TI>
<YR>2007</YR>
<PB>Stata Corp</PB>
<CY>Texas</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stepanova-2012" MODIFIED="2014-12-05 12:29:33 +0100" MODIFIED_BY="[Empty name]" NAME="Stepanova 2012" TYPE="JOURNAL_ARTICLE">
<AU>Stepanova M, Mishra A, Venkatesan C, Younossi ZM</AU>
<TI>In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>9</NO>
<PG>1034-41.e1</PG>
<IDENTIFIERS MODIFIED="2014-11-11 09:33:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22642955"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2017-05-10 12:53:06 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA)</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 23 April 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2017-05-10 12:40:39 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<TI>TSA - Trial Sequential Analysis</TI>
<YR>2011</YR>
<EN>0.9 Beta</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<MD>www.ctu.dk/tsa/downloads.aspx</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tygstrup-1984" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Tygstrup 1984" TYPE="BOOK_SECTION">
<AU>Tygstrup N, Vilstrup H</AU>
<TI>Effect of branched chain amino acids on the outcome of hepatic encephalopathy</TI>
<SO>Advances in Hepatic Encephalopathy and Urea Cycle Diseases</SO>
<YR>1984</YR>
<PG>11-4</PG>
<PB>Karger</PB>
<CY>Basel</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wein-2004" MODIFIED="2017-05-10 12:51:25 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Wein 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wein C, Koch H, Popp B, Oehler G, Schauder P</AU>
<TI>Minimal hepatic encephalopathy impairs fitness to drive</TI>
<SO>Hepatology (Baltimore, Md.)</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>739-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weir-2012" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NAME="Weir 2012" TYPE="JOURNAL_ARTICLE">
<AU>Weir MC, Grimshaw JM, Mayhew A, Fergusson D</AU>
<TI>Decisions about lumping vs. splitting of the scope of systematic reviews of complex interventions are not well justified: a case study in systematic reviews of health care professional reminders</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2012</YR>
<VL>65</VL>
<NO>7</NO>
<PG>756-63</PG>
<IDENTIFIERS MODIFIED="2014-12-21 17:59:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22498429"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weissenborn-2013" MODIFIED="2015-02-17 13:33:11 +0100" MODIFIED_BY="Anne Lawson" NAME="Weissenborn 2013" TYPE="JOURNAL_ARTICLE">
<AU>Weissenborn K</AU>
<TI>Psychometric tests for diagnosing minimal hepatic encephalopathy</TI>
<SO>Metabolic Brain Disease</SO>
<YR>2013</YR>
<VL>28</VL>
<PG>227-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2014-03-21 15:56:46 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2011-03-09 17:53:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18083463"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2014-03-21 13:39:43 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in a random-effects meta-analysis</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2014-12-05 12:29:51 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2011-03-09 17:09:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18316340"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wright-2007" MODIFIED="2011-03-09 15:28:06 +0100" MODIFIED_BY="[Empty name]" NAME="Wright 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wright G, Jalan R</AU>
<TI>Management of hepatic encephalopathy in patients with cirrhosis</TI>
<SO>Best Practice &amp; Research Clinical Gastroenterology</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>95-110</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-05-10 12:38:00 +0200" MODIFIED_BY="Sarah  Klingenberg">
<REFERENCE ID="REF-Als_x002d_Nielsen-2003" MODIFIED="2014-12-21 19:26:55 +0100" MODIFIED_BY="[Empty name]" NAME="Als-Nielsen 2003" TYPE="COCHRANE_REVIEW">
<AU>Als-Nielsen B, Koretz RL, Gluud LL, Gluud C</AU>
<TI>Branched-chain amino acids for hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-03-21 15:58:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-03-21 15:58:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001939"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2015a" MODIFIED="2017-05-10 12:35:53 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Gluud 2015a" TYPE="COCHRANE_REVIEW">
<AU>Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H</AU>
<TI>Branched-chain amino acids for people with hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-05-10 12:35:53 +0200" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER MODIFIED="2017-05-10 12:35:53 +0200" MODIFIED_BY="Sarah  Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD001939.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2015b" MODIFIED="2017-05-10 12:38:00 +0200" MODIFIED_BY="Sarah  Klingenberg" NAME="Gluud 2015b" TYPE="COCHRANE_REVIEW">
<AU>Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, et al</AU>
<TI>Branched-chain amino acids for people with hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2017-05-10 12:38:00 +0200" MODIFIED_BY="Sarah  Klingenberg"><IDENTIFIER MODIFIED="2017-05-10 12:38:00 +0200" MODIFIED_BY="Sarah  Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD001939.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-11-28 12:58:21 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Country of origin" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Type of hepatic encephalopathy" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="BCAA mode of administration">
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calvey-1985">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus non-isonitrogenous diet.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>26 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 47%.</LI>
<LI>Proportion with alcoholic liver disease 100%.</LI>
<LI>Proportion with viral hepatitis 0%.</LI>
<LI>Proportion of men 48%.</LI>
<LI>Median age BCAA group 49 years.</LI>
<LI>Median age control groups 49 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA 20 g/day versus standard diet or standard diet plus conventional protein supplements for 3 weeks (2 control groups).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy was graded clinically using a modified 0- to 5-point Glasgow Coma Score and the Reitan Trail-Making Test.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 3 weeks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>UK.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-05 13:35:21 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>Oral or intravenous (people who deteriorated).</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The trial included 64 people with acute alcoholic hepatitis. Only people with overt hepatic encephalopathy at baseline were included in our analyses.</LI>
<LI>The inclusion period was August 1980 to March 1983.</LI>
<LI>The trial included 3 intervention arms. We combined data from the 2 control arms in our analyses.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cerra-1985">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus neomycin.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>75 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 100%.</LI>
<LI>Proportion with viral hepatitis 0%.</LI>
<LI>Proportion of men 86%.</LI>
<LI>Mean age BCAA group 53 years.</LI>
<LI>Mean age control group 53 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA (36% BCAA solution 1.5 to 3 L/day) versus neomycin (4 g/day) for 4 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy was assessed using a 0- to 4-point score.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 4 days.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-05 13:36:46 +0200" MODIFIED_BY="[Empty name]">
<P>USA.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-05 13:36:47 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-06-05 13:36:48 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The investigators crossed participants classed as non-responders over after 4 days. Data received on the number of people with clinical outcomes after the first 4 days of treatment received and included in our analyses (used in the previous version of this review).</LI>
<LI>The investigators classed participants as having acute hepatic encephalopathy.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Egberts-1985">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over randomised clinical trial comparing BCAA versus isonitrogenous diet.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>22 people with minimal hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 86%.</LI>
<LI>Proportion with viral hepatitis 14%.</LI>
<LI>Proportion of men 73%.</LI>
<LI>Mean age BCAA group 51 years.</LI>
<LI>Mean age control group 52 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>Oral BCAA (0.25 g/kg/day) versus isonitrogenous diet for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy was assessed the following scales: Culture Fair Intelligence Test, Wechsler Adult Intelligence Test, Digit Symbols, Multiple Choice Vocabulary Test, Visual Retention Test, Number Revision Test, Attention Stress Test, Attention Diagnostic Method, Motor Performance Test Battery, and Vienna Reaction Time Apparatus.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 7 days.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-18 20:42:21 +0200" MODIFIED_BY="[Empty name]">
<P>Germany.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-18 20:42:28 +0200" MODIFIED_BY="[Empty name]">
<P>Minimal.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-06-05 13:37:01 +0200" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Only data from the first treatment period were included in the analyses of mortality and hepatic encephalopathy. Additional information received on the study design.</LI>
<LI>Trial inclusion period was June 1983 to June 1986.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiaccadori-1984">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA alone or with lactulose versus lactulose alone.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>48 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 52%.</LI>
<LI>Proportion with viral hepatitis 32%.</LI>
<LI>Proportion of men 73%.</LI>
<LI>Mean age in BCAA group 51 years.</LI>
<LI>Mean age control group 51 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA (2 L/day) alone or with lactulose versus lactulose 150-300 mL/day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatic encephalopathy was graded based on clinical evaluations, asterixis, blood ammonia, electroencephalography, and Reitan Number Connection Test.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-18 20:44:36 +0200" MODIFIED_BY="[Empty name]">
<P>Italy.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-18 20:44:44 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-18 20:44:51 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Abstract.</LI>
<LI>The investigators provided additional data on the design and number of participants with clinical outcomes (unpublished information/data also used in the previous version of this review).</LI>
<LI>The investigators classed participants as having acute hepatic encephalopathy.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayashi-1991">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus isonitrogenous diet.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>77 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 58%.</LI>
<LI>Proportion with viral hepatitis 9%.</LI>
<LI>Proportion of men 68%.</LI>
<LI>Mean age BCAA group and control group not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA (11 g/day) versus isonitrogenous diet for 3 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical hepatic encephalopathy was assessed using a 4-point score, the Number Connection Test and Serial Seven Test.</LI>
<LI>Hepatic encephalopathy reported after 3 weeks. Mortality not reported.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-18 21:09:37 +0200" MODIFIED_BY="[Empty name]">
<P>Japan.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-18 21:09:34 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-18 21:09:32 +0200" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-20 21:00:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Abstract.</LI>
<LI>The investigators classed the type of hepatic encephalopathy as chronic.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horst-1984">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus isonitrogenous diet.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>37 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 38%.</LI>
<LI>Proportion with viral hepatitis 8%.</LI>
<LI>Proportion of men 65%.</LI>
<LI>Mean age BCAA group 57 years.</LI>
<LI>Mean age control group 60 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA 20 g/day increased to 80 g/day versus isonitrogenous placebo for 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy graded using a 4-point score, the Number Connection Test, and electroencephalography.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 4 weeks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 09:45:31 +0200" MODIFIED_BY="[Empty name]">
<P>USA.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 09:56:10 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 09:56:13 +0200" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>The primary investigators classed participants as having chronic intermittent hepatic encephalopathy and sensitivity to dietary protein.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hwang-1988">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus no intervention.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>55 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 15%.</LI>
<LI>Proportion with viral hepatitis 65%.</LI>
<LI>Proportion of men 90%.</LI>
<LI>Mean age BCAA group 60 years.</LI>
<LI>Mean age control group 62 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Intravenous BCAA 40 g/day versus no intervention for 5 days.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy graded using a 0- to 4-point scale.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 5 days.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 09:58:43 +0200" MODIFIED_BY="[Empty name]">
<P>China.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 09:58:48 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 09:58:54 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>The investigators included 60 episodes of acute hepatic encephalopathy (in 55 participants). We only included each person once in our analyses and used data from the first time the person was randomised.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Les-2011">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus isocaloric diet.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>40 people with minimal hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 36%.</LI>
<LI>Proportion with viral hepatitis 53%.</LI>
<LI>Proportion of men 76%.</LI>
<LI>Mean age BCAA group 64 years.</LI>
<LI>Mean age control group 63 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 11:39:44 +0200" MODIFIED_BY="[Empty name]">
<P>Enteral BCAA 29 g/day versus isocaloric placebo for 56 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy was assessed using a 4-point score, Trail Making Test part A, Symbol Digit Test (oral version), and Grooved Pegboard Test (dominant hand).</LI>
<LI>Mortality and hepatic encephalopathy assessed after 56 weeks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 10:09:30 +0200" MODIFIED_BY="[Empty name]">
<P>Spain.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 10:09:35 +0200" MODIFIED_BY="[Empty name]">
<P>Minimal.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 10:09:38 +0200" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Trial included people with previous episodes of hepatic encephalopathy. We re-calculated clinical outcomes for people with minimal hepatic encephalopathy at baseline.</LI>
<LI>2 of the authors of this review (IL and JC) were investigators in the trial with access to the data and protocol.</LI>
<LI>Trial inclusion period was January 2003 to December 2008.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marchesini-1990">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus isonitrogenous control versus isocaloric casein-based control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>64 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 56%.</LI>
<LI>Proportion with viral hepatitis 41%.</LI>
<LI>Proportion of men 80%.</LI>
<LI>Mean age BCAA group 60 years.</LI>
<LI>Mean age both control groups 60 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA 2.4 g/10 kg/day versus isonitrogenous diet versus and isocaloric diet for 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy was assessed using a 12-point score.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 3 months.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 10:18:32 +0200" MODIFIED_BY="[Empty name]">
<P>Italy.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 10:18:38 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 10:18:45 +0200" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The trial included 2 control groups.</LI>
<LI>1 of the authors of this review (GM) was an investigator in the trial with access to the participant data and trial protocol. In our analyses of the data, we combined the 2 control groups.</LI>
<LI>Trial inclusion period was January 1985 to December 1986.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marchesini-2003">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus isonitrogenous and isocaloric casein-based control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]">
<P>112 people with minimal hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 21%.</LI>
<LI>Proportion of men 63%.</LI>
<LI>Proportion with viral hepatitis 68%.</LI>
<LI>Mean age BCAA group 59 years.</LI>
<LI>Mean age control group 60 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 10:27:42 +0200" MODIFIED_BY="[Empty name]">
<P>BCAA 7.2 g/day versus isonitrogenous versus isocaloric supplements for 12 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy was assessed using a 4-point score and the Reitan Test.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 12 months.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-05 13:40:42 +0200" MODIFIED_BY="[Empty name]">
<P>Italy.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 11:32:50 +0200" MODIFIED_BY="[Empty name]">
<P>Minimal.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The trial included people with previous episodes of hepatic encephalopathy.</LI>
<LI>1 of the authors of this review (GM) was an investigator in the trial with access to the patient data and trial protocol. We re-calculated clinical outcomes for people with minimal hepatic encephalopathy at baseline.</LI>
<LI>Trial inclusion period was March 1999 to March 2000.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michel-1985">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus isonitrogenous and isocaloric control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>70 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 81%.</LI>
<LI>Proportion with viral hepatitis 11%.</LI>
<LI>Proportion of men 30%.</LI>
<LI>Mean age BCAA group 61 years.</LI>
<LI>Mean age control group 59 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA 6.25 to 12.5 g/day versus isonitrogenous and isocaloric control for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy assessed using 3-point scale.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 5 and 36 days (1 month after treatment).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 11:43:13 +0200" MODIFIED_BY="[Empty name]">
<P>France.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 11:43:23 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 11:43:31 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>We used the maximum duration of follow-up in our analyses (as specified in the methods section).</LI>
<LI>The investigators classed participants as having acute hepatic encephalopathy.</LI>
<LI>Trial inclusion period was January 1979 to January 1984.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muto-2005">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus non-isonitrogenous control diet.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>39 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 8%.</LI>
<LI>Proportion with viral hepatitis 81%.</LI>
<LI>Proportion of men 47%.</LI>
<LI>Mean age BCAA group 62 years.</LI>
<LI>Mean age control group 61 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA 12 g/day versus standard diet for 2 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatic encephalopathy was assessed using a 4-point scale.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>Japan.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 11:50:56 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 11:51:03 +0200" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The trial included people with cirrhosis. A subgroup of people had hepatic encephalopathy (assessed as a grade of at least 1 using the West Haven Criteria).</LI>
<LI>We received data from the authors and the pharmaceutical company that funded the trial, which allowed re-calculation of clinical outcomes for people with hepatic encephalopathy at baseline.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plauth-1993">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over randomised clinical trial comparing BCAA versus placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>23 people with minimal hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 88%.</LI>
<LI>Proportion with viral hepatitis 12%.</LI>
<LI>Proportion of men 65%.</LI>
<LI>Mean age BCAA group 52 years.</LI>
<LI>Mean age control group 49 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA 0.25 g/kg/day versus placebo for 8 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy assessed using psychometric tests including the Digit Symbol and Number Connection Test, and test batteries on psychomotor function, attention, and reaction time.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 8 weeks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 13:55:25 +0200" MODIFIED_BY="[Empty name]">
<P>Germany.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 13:55:30 +0200" MODIFIED_BY="[Empty name]">
<P>Minimal.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>Oral.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-20 21:57:20 +0100" MODIFIED_BY="[Empty name]">
<P>We only included data from the first treatment period in our analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial on BCAA versus lactulose.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>40 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 32%.</LI>
<LI>Proportion with viral hepatitis 12%.</LI>
<LI>Proportion of men 62%.</LI>
<LI>Mean age BCAA group 59 years.</LI>
<LI>Mean age control group 59 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA (57 g/day) versus lactulose (dose not reported) for 2 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy assessed using a 4-point scale.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 2 days.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 13:56:37 +0200" MODIFIED_BY="[Empty name]">
<P>Italy.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 13:56:44 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 13:56:54 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The investigators included people with acute hepatic encephalopathy and crossed participants classed as non-responders after 48 hours to the alternative treatment. Remaining participants continued on the allocated intervention. We included data from the first 48 hours in our analyses.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strauss-1986">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus neomycin.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>32 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 75%.</LI>
<LI>Proportion with viral hepatitis 13%.</LI>
<LI>Proportion of men 90%.</LI>
<LI>Mean age BCAA group 51 years.</LI>
<LI>Mean age control group 54 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA (1.2 to 1.5 g/kg/day) versus neomycin (6 g/day) for a maximum of 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatic encephalopathy assessed using a 4-point scale.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 14:36:04 +0200" MODIFIED_BY="[Empty name]">
<P>Brazil.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 14:36:07 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 14:36:11 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>The primary investigators provided additional information about clinical outcome measures (also used in the previous version of this review). The investigators included 3 participants twice. We only included the first randomisation period in our analyses (each participant was only included once in our analysis).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vilstrup-1990">
<CHAR_METHODS MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial comparing BCAA versus isonitrocaloric control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>77 people with overt hepatic encephalopathy.</P>
<UL>
<LI>Proportion with cirrhosis 100%.</LI>
<LI>Proportion with alcoholic liver disease 91%.</LI>
<LI>Proportion with viral hepatitis 9%.</LI>
<LI>Proportion of men 72%.</LI>
<LI>Mean age BCAA group 55 years.</LI>
<LI>Mean age control group 56 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA (12.5 mL/kg/day) versus isocaloric placebo for a maximum of 16 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy assessed using a 4-point scale.</LI>
<LI>Mortality and hepatic encephalopathy assessed after 16 days.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-24 15:19:06 +0200" MODIFIED_BY="[Empty name]">
<P>Denmark.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-24 15:19:09 +0200" MODIFIED_BY="[Empty name]">
<P>Overt.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-07-24 15:19:14 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>1 of the authors of this review (HV) was an investigator in the trial with access to the protocol. The original trial data were no longer available, but all necessary data for our analyses of mortality and hepatic encephalopathy were included in the published trial.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BCAA: branched-chain amino acids; CHBG: Cochrane Hepato-Biliary Group.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-11-25 20:31:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eriksson-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-25 20:31:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised cross-over trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayashi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Compared BCAA plus zinc versus BCAA alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-18 15:37:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malaguarnera-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-18 15:37:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial comparing BCAA plus L-acetylcarnitine versus BCAA alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 18:51:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Keefe-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 18:51:42 +0100" MODIFIED_BY="[Empty name]">
<P>Compared different BCAA supplements.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-02 14:06:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wahren-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-02 14:06:03 +0200" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walker-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Compared different BCAA supplements.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BCAA: branched-chain amino acids.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-07-24 10:35:30 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" STUDY_ID="STD-ACTRN12610001021066">
<CHAR_STUDY_NAME MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>The Effects of Supplementation with Synbiotics, Branched Chain Amino Acids on Levels of Hepatic Encephalopathy in Patients with Cirrhosis.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel arm randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with Childs B or C cirrhosis on lactulose.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>BCAA plus synbiotics versus BCAAs plus placebo versus synbiotics plus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Levels of hepatic encephalopathy assessed using the Trail Making Tests A and B and the Inhibitory Control Test; biochemical markers for liver function and inflammatory processes and quality of life and nutritional responses.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>2010.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Helen Vidot, Department Nutrition and Dietetics, RPAH, Camperdown NSW, Australia. Tel: + 61 2 9515 8053. Email: helen.vidot@sswahs.nsw.gov.au.</P>
<P>
<A HREF="http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610001021066">www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610001021066</A>.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov">
<P>Trial ID: ACTRN12610001021066.</P>
<P>Still recruiting (February 2015).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>BCAA: branched-chain amino acids.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 22:39:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 20:15:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Block randomisation (table of random numbers).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 20:57:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 21:24:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 15:40:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 10:04:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-07 16:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Random number sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 22:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>Not clearly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>Computer generated (minimisation method).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 21:12:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>Computer-generated (block randomisation).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 15:27:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 22:03:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>Table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 22:39:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 16:52:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-11 23:35:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Identically appearing drug containers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 20:57:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 21:10:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 09:57:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Numbered identical coded drug containers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 10:04:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 11:42:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Central randomisation via identically appearing coded drug containers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 10:24:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-15 10:16:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 22:45:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>Not clearly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-15 13:57:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 21:50:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>Administration of coded drug containers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 15:27:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 15:07:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>Serially numbered opaque sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-19 22:40:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>No blinding reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Double-blind, double-dummy trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 09:14:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-18 20:57:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>Open trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-11 23:36:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>Open trial without blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 11:38:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 10:04:45 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>Open trial without blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 10:14:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 10:25:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Double blinding, with blinded administration of active interventions and controls.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 11:33:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Double blinding using identically appearing packets of BCAA and control supplements. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-20 22:46:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>Open trial without blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-11 23:37:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>Open trial without blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-03 19:57:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>Double blinding achieved using a placebo control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 15:38:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>Open trial without blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 15:16:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>Open trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-19 22:41:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>No blinding reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>Participants and personnel not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>Participants and personnel not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:36:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>Participants and personnel not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>Participants and personnel not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>Participants and personnel not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>Participants and personnel not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>Participants and personnel not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-01-20 22:46:39 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 22:39:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>Outcome assessment blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:36:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:36:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:37:11 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:38:07 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:38:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:39:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:38:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:40:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 11:34:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-20 22:46:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 15:28:01 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 13:55:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 15:39:42 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 15:16:37 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 15:34:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>Blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>All participants were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>All participants were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>All participants were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>Participants excluded or lost to follow-up after randomisation were not described in the published report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>Participants with missing outcomes were not accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:36:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>All participants randomised were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>All participants randomised were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>All participants accounted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>All participants accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Participants with missing outcomes were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>All participants accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>All participants were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>Participants with missing outcomes were accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>Participants lost to follow-up or excluded after randomisation were not accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>All participants accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>Only participants who completed the trial were included in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 20:09:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>Clinically relevant outcomes are defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Clinically relevant outcomes were defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 20:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Clinically relevant outcome measures defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 20:46:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>Clinically relevant outcomes not described in the published report (abstract). Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>Mortality was not reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:36:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Clinically relevant outcome measures were defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>Clinically relevant outcomes were accounted for. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Clinically relevant outcome measures defined and reported. All outcomes were described as specified in the trial protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Clinically relevant outcomes defined and reported. All outcomes were described as specified in the trial protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Clinically relevant outcome measures were defined and reported. All outcomes were described as specified in the trial protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 21:12:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>Clinically relevant outcomes defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>Clinically relevant outcomes were defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 21:12:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>Clinically relevant outcome measures defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 21:12:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>Clinically relevant outcomes defined and reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>Clinically relevant outcome measures were reported. Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-20 21:22:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>Primary outcome measures were specified and reported as specified in the trial protocol. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov" NO="9">
<NAME>For-profit funding</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:38:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:38:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:39:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:39:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:40:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:41:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:41:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:41:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:41:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:42:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:42:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>A pharmaceutical company producing BCAA funded the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>A pharmaceutical company supported the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>No for-profit funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:50:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>A pharmaceutical company funded the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-05 11:09:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-05 11:03:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-05 11:03:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-18 20:58:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-05 11:04:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:40:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-01 19:06:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 10:16:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 10:25:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 11:48:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-05 11:05:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-05 11:06:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-05 11:06:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-01 19:06:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 22:44:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>No other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>CHBG combined assessment (mortality)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:36:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>High risk of bias when domains (excluding blinding) were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>Low risk of bias when domains (except blinding) were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2015-02-19 09:08:12 +0100" MODIFIED_BY="Chavdar S Pavlov" NO="11">
<NAME>CHBG combined assessment (hepatic encephalopathy)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Calvey-1985">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerra-1985">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egberts-1985">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fiaccadori-1984">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashi-1991">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:36:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horst-1984">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-1988">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Les-2011">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-1990">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marchesini-2003">
<DESCRIPTION>
<P>Low risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michel-1985">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muto-2005">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Plauth-1993">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rossi_x002d_Fanelli-1986">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Strauss-1986">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-18 15:37:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vilstrup-1990">
<DESCRIPTION>
<P>High risk of bias when domains were combined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-09-08 12:55:27 +0200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-09-08 12:55:27 +0200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-02-19 09:08:11 +0100" MODIFIED_BY="Chavdar S Pavlov">Branched-chain amino acids (BCAA) versus control for hepatic encephalopathy</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>BCAA versus control for hepatic encephalopathy.</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with hepatic encephalopathy.<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> BCAA versus control.<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>BCAA versus control</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality</B>
<BR/>Clinically<BR/>Follow-up: 1 to 104 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.69 to 1.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>760<BR/>(15 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>226 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>199 per 1000</B>
<BR/>(156 to 251)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>171 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
<BR/>(118 to 190)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hepatic encephalopathy</B>
<BR/>Psychometric and clinical assessments<BR/>Follow-up: 1 to 104 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.73 </B>
<BR/>(0.61 to 0.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>827<BR/>(16 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>633 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>462 per 1000</B>
<BR/>(386 to 557)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>624 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>456 per 1000</B>
<BR/>(381 to 549)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Nausea and diarrhoea</B>
<BR/>Clinically<BR/>Follow-up: 1 to 104 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.39 </B>
<BR/>(0.7 to 16.46)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>945<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>74 per 1000</B>
<BR/>(15 to 360)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>35 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>119 per 1000</B>
<BR/>(24 to 576)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Albumin</B>
<BR/>Laboratory assessment<BR/>Follow-up: 1 to 104 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean albumin in the intervention groups was<BR/>
<B>0.6 higher</B>
<BR/>(0.9 lower to 2.09 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>176<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Nitrogen balance</B>
<BR/>Laboratory assessment<BR/>Follow-up: 1 to 104 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean nitrogen balance in the intervention groups was<BR/>
<B>0.81 standard deviations higher</B>
<BR/>(0.07 to 1.56 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>108<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD 0.81 (95% CI 0.07 to 1.56)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g., the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>BCAA:</B> branched-chain amino acids; <B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>SMD:</B> standardised mean difference.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The trial sequential analysis showed that additional evidence is needed and that we have not yet reached the required information size.<BR/>
<SUP>2</SUP> An analysis of trials with a low risk of bias (RR 0.71; 95% CI 0.52 to 0.96) and trial sequential analysis confirmed the result. No publication bias detected in funnel plots or regression analyses. </P>
<P>
<SUP>3</SUP> Downgraded due to imprecision and lack of trials with a low risk of bias in the overall assessment.<BR/>
<SUP>4</SUP> Indirect outcome used as a surrogate estimate of nutritional status.<BR/>
<SUP>5</SUP> Due to the small number of trials, we were unable to determine the risk of publication bias.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-06-05 13:04:57 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-09-09 11:55:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2015-09-09 11:55:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Branched-chain amino acids (BCAA) versus control</NAME>
<DICH_OUTCOME CHI2="12.065146583149485" CI_END="1.1132734750817086" CI_START="0.6939361594242381" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8789429558777271" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="8.828293761777397" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.04660186166623639" LOG_CI_START="-0.15868048182912614" LOG_EFFECT_SIZE="-0.056039310081444894" METHOD="MH" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3587665599946952" P_Q="1.0" P_Z="0.28457996481719583" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="367" TOTAL_2="393" WEIGHT="100.0" Z="1.0700874474436775">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.135195398609785"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="8.91899424826223"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.5145573604766671"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="15.324453753832378"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.020321117577006"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="2.61826535697092"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="5.912815383334559"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="25.22801230222745"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="6.174688325720005"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="8.91899424826223"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="2.2297485620655575"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2015-01-21 17:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="11.003953942661193"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.065146583149483" CI_END="1.1988533855724948" CI_START="0.7109023590289811" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9231834595211112" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="8.828293761777383" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.0787660740661652" LOG_CI_START="-0.14819004462452762" LOG_EFFECT_SIZE="-0.0347119852791812" METHOD="MH" MODIFIED="2015-02-18 15:45:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3587665599946954" P_Q="0.9905514908199858" P_Z="0.5488151664026661" Q="1.4023833867603974E-4" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01945117706799762" TOTALS="YES" TOTAL_1="367" TOTAL_2="393" WEIGHT="100.0" Z="0.5995365216110362">
<NAME>Mortality: mode of administration</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.474551635860738" CI_END="1.627849081134998" CI_START="0.497780968669576" DF="4" EFFECT_SIZE="0.9001734790890356" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.2116141387175143" LOG_CI_START="-0.30296171150360757" LOG_EFFECT_SIZE="-0.045673786393046686" MODIFIED="2015-02-18 15:45:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4817584019810389" P_Z="0.727890453232223" STUDIES="8" TAU2="0.0" TOTAL_1="158" TOTAL_2="205" WEIGHT="18.308559890034637" Z="0.347933064987326">
<NAME>Oral</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.6880882356403992"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.233758649175916"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="0.7535302796660828"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="6.179716592055935"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="4.453466133496304"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.659116561576717" CI_END="1.277604933915208" CI_START="0.6289745796825374" DF="6" EFFECT_SIZE="0.8964268103474226" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="68" I2="30.70886669173703" ID="CMP-001.02.02" LOG_CI_END="0.10639658031265216" LOG_CI_START="-0.20136690642546365" LOG_EFFECT_SIZE="-0.047485163056405766" MODIFIED="2015-02-18 15:45:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19367624574087072" P_Z="0.5453052854108432" STUDIES="7" TAU2="0.06492899435168914" TOTAL_1="209" TOTAL_2="188" WEIGHT="81.69144010996536" Z="0.6048099492046782">
<NAME>Intravenous</NAME>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.294225154182681"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="1.627009498082563"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="15.04542912464733"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="37.247173929429984"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="7.27054325724064"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.9870205358577726"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="11.220038610524382"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.065146583149485" CI_END="1.1988533855724948" CI_START="0.710902359028981" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9231834595211111" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="8.828293761777397" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.0787660740661652" LOG_CI_START="-0.14819004462452767" LOG_EFFECT_SIZE="-0.034711985279181255" METHOD="MH" MODIFIED="2014-12-01 21:02:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3587665599946952" P_Q="0.4467636205590335" P_Z="0.5488151664026661" Q="0.578849868994633" RANDOM="YES" SCALE="403.83567798739153" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.019451177067997663" TOTALS="YES" TOTAL_1="367" TOTAL_2="393" WEIGHT="100.00000000000003" Z="0.5995365216110363">
<NAME>Mortality: type of hepatic encephalopathy</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.814382091850826" CI_END="1.196066520287306" CI_START="0.6123881495771243" DF="9" EFFECT_SIZE="0.8558369956538998" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="74" I2="23.821661344371915" ID="CMP-001.03.01" LOG_CI_END="0.07775533399214307" LOG_CI_START="-0.21297322199575391" LOG_EFFECT_SIZE="-0.06760894400180541" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22397715506377713" P_Z="0.3619901304418056" STUDIES="11" TAU2="0.061900176536269" TOTAL_1="293" TOTAL_2="270" WEIGHT="87.58652475876816" Z="0.911579496042627">
<NAME>Overt</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.294225154182685"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="1.627009498082564"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.6880882356403997"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="15.045429124647331"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="0.7535302796660832"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="37.24717392942998"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="4.453466133496307"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="7.270543257240643"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.9870205358577735"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="11.220038610524387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13386906045932986" CI_END="2.3800356905974116" CI_START="0.5684403472375653" DF="1" EFFECT_SIZE="1.163145869786327" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.37658346970915557" LOG_CI_START="-0.24531510393113784" LOG_EFFECT_SIZE="0.06563418288900887" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7144538112008502" P_Z="0.6790916736734639" STUDIES="4" TAU2="0.0" TOTAL_1="74" TOTAL_2="123" WEIGHT="12.413475241231858" Z="0.41370294150755926">
<NAME>Minimal</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.233758649175919"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="6.179716592055939"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.065146583149481" CI_END="1.1988533855724945" CI_START="0.7109023590289811" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9231834595211112" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="8.828293761777369" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.07876607406616512" LOG_CI_START="-0.14819004462452762" LOG_EFFECT_SIZE="-0.0347119852791812" METHOD="MH" MODIFIED="2015-09-09 11:55:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="4" P_CHI2="0.3587665599946954" P_Q="0.5294638944412502" P_Z="0.5488151664026661" Q="3.172009187119839" RANDOM="YES" SCALE="130.0894472369696" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01945117706799759" TOTALS="YES" TOTAL_1="379" TOTAL_2="404" WEIGHT="99.99999999999999" Z="0.5995365216110363">
<NAME>Mortality: type of control</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3710510294481688" CI_START="0.40020162138967574" DF="0" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2015-01-06 15:43:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3393989432388661" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="15.045429124647328" Z="0.9553535581077968">
<NAME>Placebo/no intervention</NAME>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="15.045429124647328"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.17765727452626784" CI_END="1.4986066763711796" CI_START="0.800689438362255" DF="1" EFFECT_SIZE="1.0954079322469623" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.17568766307103975" LOG_CI_START="-0.0965359000943589" LOG_EFFECT_SIZE="0.03957588148834044" MODIFIED="2014-12-01 18:52:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.673394325453331" P_Z="0.5687594906851978" STUDIES="4" TAU2="0.0" TOTAL_1="90" TOTAL_2="140" WEIGHT="43.42689052148593" Z="0.5698794143433059">
<NAME>Isonitrogenous</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 18:51:49 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 18:51:49 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2014-12-01 18:51:49 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="6.179716592055935"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2014-12-01 18:51:49 +0100" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="37.24717392943"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2756280164935876" CI_END="1.526810052916683" CI_START="0.5437012651682672" DF="4" EFFECT_SIZE="0.911113910245272" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.18378501079492154" LOG_CI_START="-0.26463965641348536" LOG_EFFECT_SIZE="-0.04042732280928193" MODIFIED="2014-12-21 15:38:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5128032044813535" P_Z="0.7237903984970115" STUDIES="6" TAU2="0.0" TOTAL_1="142" TOTAL_2="138" WEIGHT="23.34888190850308" Z="0.3533975826568077">
<NAME>Non-isonitrogenous</NAME>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2014-12-01 18:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.6880882356403991"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2014-12-01 18:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.233758649175915"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2014-12-01 18:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="0.7535302796660825"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 18:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="4.453466133496303"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 18:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2014-12-01 18:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="11.220038610524382"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.38509663133377" CI_END="2.080238954827148" CI_START="0.03693718619783953" DF="1" EFFECT_SIZE="0.2771969942305462" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="70.4587458229815" ID="CMP-001.04.04" LOG_CI_END="0.318113224771542" LOG_CI_START="-1.4325361913347532" LOG_EFFECT_SIZE="-0.5572114832816056" MODIFIED="2014-12-01 18:52:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.06578841082733744" P_Z="0.21215276790406756" STUDIES="2" TAU2="1.547828334709312" TOTAL_1="52" TOTAL_2="36" WEIGHT="8.8975527553232" Z="1.2476677842593002">
<NAME>Lactulose</NAME>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="1.627009498082563"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="7.2705432572406385"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06732083731844114" CI_END="2.8419168155290757" CI_START="0.5425122695508099" DF="1" EFFECT_SIZE="1.2416822224173498" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="0.45361136173873473" LOG_CI_START="-0.2655904352896532" LOG_EFFECT_SIZE="0.09401046322454074" MODIFIED="2014-12-01 18:52:43 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7952783445747598" P_Z="0.6083757207994156" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="51" WEIGHT="9.281245690040453" Z="0.5123933862549963">
<NAME>Neomycin</NAME>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.294225154182681"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.9870205358577722"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.065146583149485" CI_END="1.1988533855724948" CI_START="0.7109023590289811" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9231834595211111" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="8.828293761777397" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.0787660740661652" LOG_CI_START="-0.14819004462452762" LOG_EFFECT_SIZE="-0.034711985279181255" METHOD="MH" MODIFIED="2015-02-18 15:45:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3587665599946952" P_Q="0.8452106412628642" P_Z="0.548815166402666" Q="0.03811591706455509" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.019451177067997653" TOTALS="YES" TOTAL_1="367" TOTAL_2="393" WEIGHT="99.99999999999997" Z="0.5995365216110365">
<NAME>Mortality: type of data</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.73448640841539" CI_END="1.5650562963083123" CI_START="0.46830808346020286" DF="3" EFFECT_SIZE="0.8561124427500567" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.19452996407819778" LOG_CI_START="-0.3294683458013871" LOG_EFFECT_SIZE="-0.06746919086159466" MODIFIED="2015-02-18 15:45:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.43439854425372426" P_Z="0.6137529111111963" STUDIES="4" TAU2="0.0" TOTAL_1="108" TOTAL_2="147" WEIGHT="17.620471654394244" Z="0.5047237048729133">
<NAME>Re-calculated outcomes</NAME>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.233758649175917"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="0.7535302796660831"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="6.179716592055938"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="4.453466133496305"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.190414266874976" CI_END="1.2854205914061845" CI_START="0.6543774606141087" DF="7" EFFECT_SIZE="0.917142443912321" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="68" I2="23.833683697696735" ID="CMP-001.05.02" LOG_CI_END="0.10904525267913649" LOG_CI_START="-0.18417166792398543" LOG_EFFECT_SIZE="-0.037563207622424453" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2392729175419267" P_Z="0.6155471608816085" STUDIES="11" TAU2="0.05280607421235599" TOTAL_1="259" TOTAL_2="246" WEIGHT="82.37952834560573" Z="0.5021711157208607">
<NAME>Trial reports</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.2942251541826835"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="1.6270094980825636"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.6880882356403994"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="15.045429124647331"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="37.24717392942997"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="7.270543257240641"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.987020535857773"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2014-10-02 17:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="11.220038610524385"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="46.30723314661928" CI_END="1.075414034216175" CI_START="0.8447600015240156" CI_STUDY="95" CI_TOTAL="95" DF="57" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9531352271233101" ESTIMABLE="YES" EVENTS_1="349" EVENTS_2="396" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.03157569974652402" LOG_CI_START="-0.07326665769928983" LOG_EFFECT_SIZE="-0.020845478976382892" METHOD="MH" MODIFIED="2015-01-21 16:34:33 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8433841141321429" P_Q="0.9941218097156775" P_Z="0.435751754491001" Q="0.44109334877816697" RANDOM="YES" SCALE="100.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-10" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1735" TOTAL_2="1959" WEIGHT="600.0" Z="0.7793870536593637">
<NAME>Mortality: bias control</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9947178503054195" CI_END="1.5551625024330444" CI_START="0.6956860764916792" DF="7" EFFECT_SIZE="1.0401465760288913" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="39" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.1917757761426796" LOG_CI_START="-0.15758668855458768" LOG_EFFECT_SIZE="0.017094543794045926" MODIFIED="2015-01-21 16:31:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7803856865069129" P_Z="0.8478951498835661" STUDIES="10" TAU2="0.0" TOTAL_1="242" TOTAL_2="279" WEIGHT="99.99999999999997" Z="0.1918047503901461">
<NAME>Selection bias</NAME>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="15.70544066845164"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="1.6428416790883613"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="15.852842166759773"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="4.813041835333703"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="18.783641144974897"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="1.8003867582426851"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="11.093474474122802"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="30.30833127302612"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.038131235025308" CI_END="1.272613715966711" CI_START="0.7737467394622075" DF="8" EFFECT_SIZE="0.9923107947231686" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="65" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.1046965996612899" LOG_CI_START="-0.11140116806753464" LOG_EFFECT_SIZE="-0.003352284203122368" MODIFIED="2015-01-21 16:32:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7534930236264638" P_Z="0.9515112361988766" STUDIES="12" TAU2="0.0" TOTAL_1="277" TOTAL_2="318" WEIGHT="99.99999999999999" Z="0.060809108517098434">
<NAME>Attrition bias</NAME>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.8414829933648682"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="6.0089446308021675"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.628555727611383"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="16.328967829904293"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.1866725670257265"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.065340847917556"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="0.6888329065507376"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="57.006808768213986"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="4.2443937286092694"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.065146583149481" CI_END="1.1988533855724948" CI_START="0.7109023590289812" DF="11" EFFECT_SIZE="0.9231834595211112" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="8.828293761777369" ID="CMP-001.06.03" LOG_CI_END="0.0787660740661652" LOG_CI_START="-0.14819004462452756" LOG_EFFECT_SIZE="-0.0347119852791812" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3587665599946954" P_Z="0.5488151664026661" STUDIES="15" TAU2="0.01945117706799759" TOTAL_1="367" TOTAL_2="393" WEIGHT="99.99999999999999" Z="0.5995365216110362">
<NAME>Reporting bias</NAME>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.294225154182681"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.6880882356403991"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.9870205358577722"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.233758649175915"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="15.045429124647328"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="6.179716592055935"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="0.7535302796660825"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="11.220038610524382"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="37.24717392943"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="4.453466133496303"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="7.2705432572406385"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2015-01-21 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="1.627009498082563"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.399941662766077" CI_END="1.2532743402361004" CI_START="0.6808855003584129" DF="9" EFFECT_SIZE="0.9237620506591602" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="75" I2="13.461053034346865" ID="CMP-001.06.04" LOG_CI_END="0.09804614793705728" LOG_CI_START="-0.16692591414208546" LOG_EFFECT_SIZE="-0.034439883102514154" MODIFIED="2015-01-21 16:33:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3190880120903927" P_Z="0.6104055150064815" STUDIES="12" TAU2="0.032693350313957585" TOTAL_1="290" TOTAL_2="331" WEIGHT="99.99999999999997" Z="0.5094946990489576">
<NAME>For-profit bias</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="2.668924087415346"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="1.0213759273150465"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="18.440691183891303"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="8.052582276335343"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="9.43000186906861"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="8.119877087141546"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.9331246658104303"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="2.1911565646407425"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="39.74130723839649"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2015-01-21 16:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="9.400959099985135"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.065146583149486" CI_END="1.1988533855724948" CI_START="0.710902359028981" DF="11" EFFECT_SIZE="0.9231834595211111" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="8.82829376177741" ID="CMP-001.06.05" LOG_CI_END="0.0787660740661652" LOG_CI_START="-0.14819004462452767" LOG_EFFECT_SIZE="-0.034711985279181255" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3587665599946951" P_Z="0.548815166402666" STUDIES="15" TAU2="0.019451177067997694" TOTAL_1="367" TOTAL_2="393" WEIGHT="99.99999999999999" Z="0.5995365216110364">
<NAME>Other bias</NAME>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="15.045429124647331"/>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="0.7535302796660833"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="6.233758649175918"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="7.294225154182684"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="0.6880882356403998"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.9870205358577737"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="6.179716592055939"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="1.6270094980825642"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4868856884016606" CI_START="0.132848722493165" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.1722775812962149" LOG_CI_START="-0.8766426175189399" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.37962962962962965" WEIGHT="4.453466133496306"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.492105186854527" CI_START="0.7719480032495509" EFFECT_SIZE="1.0732323232323233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17379944006711878" LOG_CI_START="-0.11241195181752023" LOG_EFFECT_SIZE="0.030693744124799267" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="829" O_E="0.0" SE="0.16812198836227615" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.02826500297088532" WEIGHT="37.24717392942995"/>
<DICH_DATA CI_END="1.5835812866480332" CI_START="0.24667189698031608" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.1996403610054535" LOG_CI_START="-0.607880326317303" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="7.270543257240642"/>
<DICH_DATA CI_END="2.3440677569113397" CI_START="0.5437224060213147" EFFECT_SIZE="1.1289473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.36997016111201103" LOG_CI_START="-0.26462276997618284" LOG_EFFECT_SIZE="0.05267369556791412" MODIFIED="2015-01-21 16:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.372763029006876" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.13895227579438107" WEIGHT="11.220038610524385"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0906472817276724" CI_END="1.439944271934024" CI_START="0.647429509012998" DF="6" EFFECT_SIZE="0.965537370061006" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="39" I2="0.0" ID="CMP-001.06.06" LOG_CI_END="0.15834568455367368" LOG_CI_START="-0.18880750989259365" LOG_EFFECT_SIZE="-0.015230912669459981" MODIFIED="2015-01-21 16:34:33 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7973867907686398" P_Z="0.8634517256984151" STUDIES="8" TAU2="0.0" TOTAL_1="192" TOTAL_2="245" WEIGHT="100.0" Z="0.17198194204395773">
<NAME>Combined bias assessment</NAME>
<DICH_DATA CI_END="4.524738913000971" CI_START="0.011268838836977872" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6555935245546377" LOG_CI_START="-1.9481208321946697" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="2.3391705069124424" WEIGHT="1.7776884727694202"/>
<DICH_DATA CI_END="80.7084650001581" CI_START="0.1517808571873595" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9069190875109077" LOG_CI_START="-0.8187829988103563" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="2.5634920634920637" WEIGHT="1.6221296352741073"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.6696102418548953" CI_START="0.4820158878644343" EFFECT_SIZE="1.32996632996633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.5646199392382869" LOG_CI_START="-0.3169386466197912" LOG_EFFECT_SIZE="0.1238406463092479" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5178318771184134" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.26814985295997956" WEIGHT="15.507435115398195"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="4.7523616525490855"/>
<DICH_DATA CI_END="2.797011353991805" CI_START="0.37088872416790253" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.44669422931967895" LOG_CI_START="-0.4307563699771281" LOG_EFFECT_SIZE="0.007968929671275373" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.5154188254774612" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.26565656565656565" WEIGHT="15.652978256732492"/>
<DICH_DATA CI_END="1.3710510294481688" CI_START="0.40020162138967574" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1370536191916473" LOG_CI_START="-0.3977211561816596" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.3141293502321117" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.09867724867724868" WEIGHT="42.14057953299222"/>
<DICH_DATA CI_END="3.3200676063201957" CI_START="0.518861798693705" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.521146927304296" LOG_CI_START="-0.28494830314830694" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2015-01-21 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.47350432860360336" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.2242063492063492" WEIGHT="18.546827334284487"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.308691623950452" CI_END="0.8781056760809306" CI_START="0.6080847043418871" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.730727466584229" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="269" I2="50.50924604034461" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.056453215555052845" LOG_CI_START="-0.216035920618674" LOG_EFFECT_SIZE="-0.13624456808686342" METHOD="MH" MODIFIED="2014-12-01 21:02:30 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.010855812620851446" P_Q="1.0" P_Z="8.179176327288427E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05663409046083308" TOTALS="YES" TOTAL_1="402" TOTAL_2="425" WEIGHT="99.99999999999997" Z="3.3466589807837694">
<NAME>Hepatic encephalopathy</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="2.7599792996389163"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.803365538391037"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="3.9085872320045825"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="0.7779310354381792"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="11.299583436994098"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="10.488900332597938"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.005499409295855"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="2.9632868919916677"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.265383804759493"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="11.14611970125815"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="10.615306603174052"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="3.719202380017237"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="11.987769628951275"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="5.326582484361063"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.9431949722208209"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 20:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="8.989307248905622"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.308691623950455" CI_END="0.8781056760809306" CI_START="0.6080847043418871" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.730727466584229" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="269" I2="50.509246040344614" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.056453215555052845" LOG_CI_START="-0.216035920618674" LOG_EFFECT_SIZE="-0.13624456808686342" METHOD="MH" MODIFIED="2014-12-01 21:02:30 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.010855812620851557" P_Q="0.33769978061517214" P_Z="8.179176327288458E-4" Q="0.9191447203329602" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05663409046083309" TOTALS="YES" TOTAL_1="402" TOTAL_2="425" WEIGHT="99.99999999999999" Z="3.3466589807837686">
<NAME>Hepatic encephalopathy: mode of administration</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.508380748517567" CI_END="0.876390082612956" CI_START="0.518351285242226" DF="8" EFFECT_SIZE="0.6740014285563246" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="175" I2="64.45768316529437" ID="CMP-001.08.01" LOG_CI_END="-0.057302545637619114" LOG_CI_START="-0.2853758203022119" LOG_EFFECT_SIZE="-0.17133918296991552" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00405624695292961" P_Z="0.0032313108113385756" STUDIES="9" TAU2="0.08439426607128313" TOTAL_1="193" TOTAL_2="237" WEIGHT="62.53881270821336" Z="2.9448310263919497">
<NAME>Oral</NAME>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="2.7599792996389163"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="3.908587232004583"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="11.299583436994098"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="10.488900332597938"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="2.963286891991668"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.265383804759493"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="11.14611970125815"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="3.7192023800172365"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="11.987769628951275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.81877033892465" CI_END="1.0756297912466763" CI_START="0.614713917232307" DF="6" EFFECT_SIZE="0.8131448840575786" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="94" I2="31.963303619361152" ID="CMP-001.08.02" LOG_CI_END="0.031662822181672545" LOG_CI_START="-0.21132695426360143" LOG_EFFECT_SIZE="-0.08983206604096448" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1840298089801996" P_Z="0.14728812105632966" STUDIES="7" TAU2="0.04157256255972657" TOTAL_1="209" TOTAL_2="188" WEIGHT="37.46118729178663" Z="1.4491771355390162">
<NAME>Intravenous</NAME>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.803365538391036"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="0.7779310354381793"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.005499409295855"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="10.615306603174053"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="5.326582484361064"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.943194972220821"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="8.989307248905622"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.308691623950466" CI_END="0.8781056760809306" CI_START="0.6080847043418871" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7307274665842289" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="269" I2="50.509246040344635" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.056453215555052845" LOG_CI_START="-0.216035920618674" LOG_EFFECT_SIZE="-0.1362445680868635" METHOD="MH" MODIFIED="2015-02-18 15:44:45 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.010855812620851557" P_Q="0.8275098782427631" P_Z="8.179176327288458E-4" Q="0.04747881586216138" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05663409046083313" TOTALS="YES" TOTAL_1="402" TOTAL_2="425" WEIGHT="100.0" Z="3.3466589807837686">
<NAME>Overt or minimal hepatic encephalopathy</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.414541307207447" CI_END="0.878805456399946" CI_START="0.579382843482717" DF="11" EFFECT_SIZE="0.7135578492295684" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="181" I2="40.26459950053384" ID="CMP-001.09.01" LOG_CI_END="-0.05610725525968496" LOG_CI_START="-0.2370343691445141" LOG_EFFECT_SIZE="-0.14657081220209953" MODIFIED="2015-02-18 15:44:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07244701451947988" P_Z="0.0014954155067480371" STUDIES="12" TAU2="0.04578191787010446" TOTAL_1="328" TOTAL_2="302" WEIGHT="69.99423654579432" Z="3.175571719822665">
<NAME>Overt</NAME>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="2.759979299638918"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.803365538391039"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="0.7779310354381797"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="11.299583436994096"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="10.48890033259794"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.005499409295856"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.265383804759494"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="10.615306603174053"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="3.719202380017238"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="5.326582484361065"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.9431949722208215"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="8.989307248905622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.469522133263276" CI_END="1.1223596766329715" CI_START="0.501756386066513" DF="3" EFFECT_SIZE="0.7504339645925816" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="88" I2="68.319415089997" ID="CMP-001.09.02" LOG_CI_END="0.05013205526694295" LOG_CI_START="-0.29950709135507925" LOG_EFFECT_SIZE="-0.12468751804406811" MODIFIED="2015-02-18 15:44:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.023657884657744987" P_Z="0.16213835170148588" STUDIES="4" TAU2="0.0982929108158836" TOTAL_1="74" TOTAL_2="123" WEIGHT="30.005763454205674" Z="1.397915805762175">
<NAME>Minimal</NAME>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="3.908587232004585"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="2.9632868919916695"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="11.146119701258149"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="11.987769628951273"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.095348017227817" CI_END="0.9021507485864095" CI_START="0.628447397919571" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7529636714213522" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="259" I2="48.33061383415893" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.04472088617313747" LOG_CI_START="-0.20173106761893614" LOG_EFFECT_SIZE="-0.12322597689603686" METHOD="MH" MODIFIED="2014-12-21 15:30:56 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.018711342533739295" P_Q="0.838359934549322" P_Z="0.002094680941420659" Q="1.4334559728319982" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04965368726946659" TOTALS="YES" TOTAL_1="391" TOTAL_2="414" WEIGHT="100.0" Z="3.0764689837565897">
<NAME>Hepatic encephalopathy: type of control</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.375335516137515" CI_END="1.9122124165760228" CI_START="0.3131213330952149" DF="1" EFFECT_SIZE="0.7737922854613547" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" I2="84.31455101509938" ID="CMP-001.10.01" LOG_CI_END="0.2815361338725125" LOG_CI_START="-0.504287342699541" LOG_EFFECT_SIZE="-0.11137560441351424" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.011571737786394198" P_Z="0.5785010203636589" STUDIES="2" TAU2="0.36439939841540714" TOTAL_1="39" TOTAL_2="39" WEIGHT="17.871853671937487" Z="0.5555755965935504">
<NAME>Placebo/no intervention</NAME>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.046067366592096"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="12.825786305345392"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.072044694523186" CI_END="0.9389274477572501" CI_START="0.5719980778861926" DF="4" EFFECT_SIZE="0.7328469795201011" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="152" I2="60.286117453638234" ID="CMP-001.10.02" LOG_CI_END="-0.027367964982045054" LOG_CI_START="-0.24260543058603642" LOG_EFFECT_SIZE="-0.13498669778404077" MODIFIED="2014-12-21 15:27:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03923151971387462" P_Z="0.013956062239073965" STUDIES="5" TAU2="0.04558851253316675" TOTAL_1="151" TOTAL_2="199" WEIGHT="50.42701120507163" Z="2.4583923185147043">
<NAME>Isonitrogenous diet</NAME>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="12.016882355841489"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="11.076370992912796"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.273785541179533"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="11.837822074958146"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="11.222150240179666"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.111770719637667" CI_END="1.1482354502257914" CI_START="0.4917469553819837" DF="3" EFFECT_SIZE="0.751426168502398" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="49" I2="27.038733320607847" ID="CMP-001.10.03" LOG_CI_END="0.06003095099683137" LOG_CI_START="-0.308258320305214" LOG_EFFECT_SIZE="-0.12411368465419134" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2496452080911391" P_Z="0.1864954102722485" STUDIES="4" TAU2="0.05397465896965623" TOTAL_1="93" TOTAL_2="89" WEIGHT="18.750149648208254" Z="1.3210178567014128">
<NAME>Non-isonitrogenous diet</NAME>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="2.7316034331637327"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="2.9376716374991334"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="3.7098673326243654"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:22 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="9.371007244921019"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.246341740238634" CI_END="2.4808410960534726" CI_START="0.03340367376153972" DF="1" EFFECT_SIZE="0.2878701211080977" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="76.45031744562786" ID="CMP-001.10.04" LOG_CI_END="0.39459894753813113" LOG_CI_START="-1.4762057665230324" LOG_EFFECT_SIZE="-0.5408034094924505" MODIFIED="2014-12-21 15:30:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.03933513350883744" P_Z="0.25714947950879574" STUDIES="2" TAU2="1.9173705903284433" TOTAL_1="52" TOTAL_2="36" WEIGHT="6.14178909214001" Z="1.1331543023758024">
<NAME>Lactulose</NAME>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-21 15:30:32 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="0.7577348575946016"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-21 15:30:16 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="5.384054234545408"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0036825115933186298" CI_END="1.6812577768232302" CI_START="0.5343128831495276" DF="1" EFFECT_SIZE="0.9477962281271144" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="0.22563430622297645" LOG_CI_START="-0.2722043541470667" LOG_EFFECT_SIZE="-0.023285023962045147" MODIFIED="2014-12-21 15:30:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9516111560171643" P_Z="0.8545282932523393" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="51" WEIGHT="6.809196382642627" Z="0.18334376968971466">
<NAME>Neomycin</NAME>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-21 15:30:47 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.889272849117768"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-21 15:30:56 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.9199235335248588"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.308691623950452" CI_END="0.8781056760809306" CI_START="0.6080847043418871" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.730727466584229" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="269" I2="50.50924604034461" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.056453215555052845" LOG_CI_START="-0.216035920618674" LOG_EFFECT_SIZE="-0.13624456808686342" METHOD="MH" MODIFIED="2015-02-18 15:46:52 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.010855812620851446" P_Q="0.4733821742962063" P_Z="8.179176327288427E-4" Q="0.5140703729523541" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.056634090460833064" TOTALS="YES" TOTAL_1="402" TOTAL_2="425" WEIGHT="99.99999999999999" Z="3.3466589807837694">
<NAME>Hepatic encephalopathy: type of data</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="20.74330035909651" CI_END="0.9239039916627252" CI_START="0.622371094120015" DF="11" EFFECT_SIZE="0.7582948886501738" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="174" I2="46.97083005320223" ID="CMP-001.11.01" LOG_CI_END="-0.03437315654770028" LOG_CI_START="-0.2059505862556643" LOG_EFFECT_SIZE="-0.12016187140168229" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03613021389261617" P_Z="0.006046165778630075" STUDIES="12" TAU2="0.046845850740448246" TOTAL_1="294" TOTAL_2="278" WEIGHT="77.90600722197344" Z="2.7452671445549597">
<NAME>Published data</NAME>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="2.7599792996389163"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.803365538391037"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="3.908587232004583"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="0.7779310354381791"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="11.299583436994098"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="10.488900332597938"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.0054994092958545"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="10.615306603174053"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="11.987769628951277"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="5.3265824843610625"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.9431949722208208"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="8.989307248905622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.900117132660782" CI_END="1.080040550863414" CI_START="0.34084006653149135" DF="3" EFFECT_SIZE="0.6067298354399548" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="95" I2="66.29257845392965" ID="CMP-001.11.02" LOG_CI_END="0.03344006167732394" LOG_CI_START="-0.46744935859210074" LOG_EFFECT_SIZE="-0.21700464845738837" MODIFIED="2015-02-18 15:46:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.030648813009546694" P_Z="0.08945790068361857" STUDIES="4" TAU2="0.2189066787314324" TOTAL_1="108" TOTAL_2="147" WEIGHT="22.093992778026546" Z="1.6982642405402752">
<NAME>Re-calculated based on unpublished data</NAME>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="2.9632868919916677"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.265383804759492"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="11.14611970125815"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="3.7192023800172365"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.30869162395047" CI_END="0.8055827754043833" CI_START="0.624308623741809" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7091771808390462" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="269" I2="50.509246040344635" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.09388982823745923" LOG_CI_START="-0.20460066600157328" LOG_EFFECT_SIZE="-0.14924524711951626" METHOD="MH" MODIFIED="2015-02-18 15:46:35 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.010855812620852112" P_Q="0.4706143753316345" P_Z="1.2617798839982638E-7" Q="0.5205332351441319" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="425" WEIGHT="100.0" Z="5.284312089504364">
<NAME>Hepatic encephalopathy: publication status</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="28.7665219286999" CI_END="0.8270854233737168" CI_START="0.6255452122333479" DF="14" EFFECT_SIZE="0.7192908498649347" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="239" I2="51.33231596541248" ID="CMP-001.12.01" LOG_CI_END="-0.08244963315128287" LOG_CI_START="-0.20374129554074452" LOG_EFFECT_SIZE="-0.1430954643460137" MODIFIED="2015-02-18 15:46:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.011236936146581944" P_Z="3.7534450721485598E-6" STUDIES="15" TAU2="0.0" TOTAL_1="367" TOTAL_2="393" WEIGHT="87.24484723884764" Z="4.6245875593438965">
<NAME>Full-paper articles</NAME>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="3.4434240237982765"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.6430415517276"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="4.069501119034326"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="3.2556008952274613"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="7.105128980800473"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.993265284396008"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="4.028806107843984"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="8.393346058008298"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="13.669163580184945"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="10.045854190987596"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="2.8173469285622263"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="4.246435950296688"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="4.883401342841192"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.8139002238068653"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="8.836631001331682"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8509710702846247" CI_START="0.4813324615876788" DF="0" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400662" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0021397556744197923" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="12.755152761152367" Z="3.070116110084661">
<NAME>Abstracts</NAME>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="12.755152761152367"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="160.00929814399555" CI_END="0.7989760625742766" CI_START="0.6748466826646032" CI_STUDY="95" CI_TOTAL="95" DF="78" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7342930922708433" ESTIMABLE="YES" EVENTS_1="817" EVENTS_2="1386" I2="51.25283286362131" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.09746623200970352" LOG_CI_START="-0.1707948826294572" LOG_EFFECT_SIZE="-0.1341305573195803" METHOD="MH" MODIFIED="2015-01-21 16:17:46 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.3352321837079018E-7" P_Q="0.9952251253177565" P_Z="7.48805788786046E-13" Q="0.6645131871132144" RANDOM="YES" SCALE="100.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-09" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05246339129881063" TOTALS="SUB" TOTAL_1="1895" TOTAL_2="2177" WEIGHT="700.0" Z="7.170214080056828">
<NAME>Hepatic encephalopathy: bias control</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.528170171720696" CI_END="0.9734626640069337" CI_START="0.6206646229688019" DF="9" EFFECT_SIZE="0.777299065566188" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="171" I2="48.6540813340558" ID="CMP-001.13.01" LOG_CI_END="-0.011680700668562779" LOG_CI_START="-0.2071430080982376" LOG_EFFECT_SIZE="-0.10941185438340016" MODIFIED="2015-01-21 16:13:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04105941672733138" P_Z="0.028219860670790256" STUDIES="10" TAU2="0.05289260076004649" TOTAL_1="242" TOTAL_2="279" WEIGHT="100.0" Z="2.194216336572816">
<NAME>Selection bias</NAME>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="17.554746532095134"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="5.962971785336725"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="6.51737231652218"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="8.926900141726462"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="4.50238519365537"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="16.471259617928784"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.4207037770645532"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="5.669395654775981"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2015-01-21 16:13:18 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="18.951615958275486"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="14.022649022619321"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.902312995907536" CI_END="0.9749135375388651" CI_START="0.5856446731647711" DF="7" EFFECT_SIZE="0.7556142667101113" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="164" I2="60.89890729985451" ID="CMP-001.13.02" LOG_CI_END="-0.01103389900384805" LOG_CI_START="-0.23236580256277697" LOG_EFFECT_SIZE="-0.12169985078331258" MODIFIED="2015-01-21 16:14:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01241862013371009" P_Z="0.03113200745710377" STUDIES="8" TAU2="0.07109929032307415" TOTAL_1="199" TOTAL_2="251" WEIGHT="100.0" Z="2.1553813130756736">
<NAME>Performance and detection bias</NAME>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="10.189913521324474"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="17.205682819462684"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="5.4350714148814605"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="7.666605113950573"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="7.0640673368398215"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="18.116622116084745"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="19.259151508025116"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="15.062886169431126"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.030098786891106" CI_END="0.9182077673304428" CI_START="0.5957500418141881" DF="11" EFFECT_SIZE="0.7396095698280436" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="199" I2="50.06831287317925" ID="CMP-001.13.03" LOG_CI_END="-0.0370590377576667" LOG_CI_START="-0.22493591849947434" LOG_EFFECT_SIZE="-0.1309974781285705" MODIFIED="2015-01-21 16:15:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.024141136917333772" P_Z="0.006272670558770238" STUDIES="12" TAU2="0.058771116197985765" TOTAL_1="277" TOTAL_2="318" WEIGHT="100.0" Z="2.7331765162783848">
<NAME>Attrition bias</NAME>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="7.931736660703794"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="15.041214859589214"/>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="3.7999291986380723"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.304311880878679"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="5.851284973814559"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="14.342932274480487"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="5.366437601728403"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="4.077839515960553"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="14.176386138292347"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="6.854370108457195"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="5.108745598300465"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="16.144811189156226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.030098786891116" CI_END="0.9182077673304428" CI_START="0.5957500418141879" DF="11" EFFECT_SIZE="0.7396095698280434" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="199" I2="50.06831287317928" ID="CMP-001.13.04" LOG_CI_END="-0.0370590377576667" LOG_CI_START="-0.2249359184994745" LOG_EFFECT_SIZE="-0.13099747812857063" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.024141136917333772" P_Z="0.006272670558770238" STUDIES="12" TAU2="0.05877111619798582" TOTAL_1="277" TOTAL_2="318" WEIGHT="100.00000000000001" Z="2.7331765162783848">
<NAME>Reporting bias</NAME>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="15.041214859589214"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="5.851284973814561"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.30431188087868"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="5.366437601728406"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="14.34293227448049"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="14.176386138292349"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="6.854370108457197"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="7.9317366607037965"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="4.077839515960556"/>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="3.799929198638074"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="16.144811189156226"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="5.108745598300468"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="30.449973966430008" CI_END="0.8559074449383708" CI_START="0.5604338374868235" DF="13" EFFECT_SIZE="0.6925889790491567" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="242" I2="57.3070242544968" ID="CMP-001.13.05" LOG_CI_END="-0.06757319598382854" LOG_CI_START="-0.25147565106262876" LOG_EFFECT_SIZE="-0.15952442352322865" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.00405452925311478" P_Z="6.731097839901786E-4" STUDIES="14" TAU2="0.07313974124230076" TOTAL_1="337" TOTAL_2="374" WEIGHT="100.00000000000001" Z="3.400303977737219">
<NAME>For-profit bias</NAME>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="1.2307728509010445"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="12.378657751739748"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="4.835641934214746"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="11.636732861978299"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="1.0182261922958131"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="6.949409976487909"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="11.753657709320157"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="6.076093488612923"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="5.244321357148444"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="12.239643747413126"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="6.430401066991388"/>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="3.484642577762455"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="3.727796391605812"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="12.994002093528144"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="30.308691623950455" CI_END="0.8781056760809306" CI_START="0.6080847043418871" DF="15" EFFECT_SIZE="0.730727466584229" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="269" I2="50.509246040344614" ID="CMP-001.13.06" LOG_CI_END="-0.056453215555052845" LOG_CI_START="-0.216035920618674" LOG_EFFECT_SIZE="-0.13624456808686342" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.010855812620851557" P_Z="8.179176327288458E-4" STUDIES="16" TAU2="0.05663409046083309" TOTAL_1="402" TOTAL_2="425" WEIGHT="100.0" Z="3.3466589807837686">
<NAME>Other bias</NAME>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.265383804759494"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="11.146119701258153"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="0.7779310354381795"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="11.2995834369941"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="10.48890033259794"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.005499409295857"/>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="2.759979299638917"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="3.9085872320045842"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.803365538391038"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.9431949722208213"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="2.963286891991669"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="5.326582484361065"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="10.615306603174055"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="3.7192023800172374"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="11.987769628951279"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="8.989307248905625"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.75781459068017" CI_END="0.9603519875875073" CI_START="0.5177478632543528" DF="6" EFFECT_SIZE="0.7051384187133067" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="142" I2="68.01333134521383" ID="CMP-001.13.07" LOG_CI_END="-0.01756956045073665" LOG_CI_START="-0.2858816847643189" LOG_EFFECT_SIZE="-0.15172562260752778" MODIFIED="2015-01-21 15:46:56 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.00459281723210736" P_Z="0.02664716039505682" STUDIES="7" TAU2="0.10066723392898726" TOTAL_1="161" TOTAL_2="212" WEIGHT="100.00000000000001" Z="2.2166479178191736">
<NAME>Combined bias assessment</NAME>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="9.239474897605453"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="7.293806297941948"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="19.435497624939085"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2015-01-21 15:46:56 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="20.216868637865804"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="9.934373731524708"/>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="12.709421489412787"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-01 21:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="21.17055732071022"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.49141814204339" CI_END="0.8930852196017065" CI_START="0.6177428825711401" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7427631102433924" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="258" I2="50.86239677434348" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.049107098068990614" LOG_CI_START="-0.20919224969421357" LOG_EFFECT_SIZE="-0.1291496738816021" METHOD="MH" MODIFIED="2015-02-18 15:43:22 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.01223508699021525" P_Q="1.0" P_Z="0.00156460585656689" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.054466710518972415" TOTALS="YES" TOTAL_1="392" TOTAL_2="409" WEIGHT="100.00000000000001" Z="3.1624258321675667">
<NAME>Hepatic encephalopathy: excluding 1 trial on people with or without cirrhosis</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="5.9247755165513105"/>
<DICH_DATA CI_END="0.8935884467566733" CI_START="0.1790533445018549" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.04886245486811941" LOG_CI_START="-0.7470175624759557" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.41009976613236215" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" VAR="0.16818181818181813" WEIGHT="3.971526619632022"/>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="0.7843423776253615"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="11.69685046649734"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="10.835378230856938"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.100035072499865"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="3.0039320386225827"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.3379233990112755"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="11.533500426449166"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="10.969471018586605"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="3.777310478223528"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="12.430937395948824"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="5.431537594420434"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="0.9513568894397152"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-21 17:23:36 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="9.251122475635048"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.95021591389441" CI_END="0.9205700471469406" CI_START="0.6305086760997842" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7618578618638345" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="226" I2="52.26779503800774" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.035943159976942494" LOG_CI_START="-0.2003089329507949" LOG_EFFECT_SIZE="-0.11812604646386865" METHOD="MH" MODIFIED="2015-02-18 15:44:05 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.021443422162835346" P_Q="1.0" P_Z="0.004844954515697642" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.045705824265750115" TOTALS="YES" TOTAL_1="283" TOTAL_2="327" WEIGHT="99.99999999999999" Z="2.8171655511530225">
<NAME>Hepatic encephalopathy: excluding trials with lactulose or neomycin controls</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.189405120790075" CI_START="0.1600911412034378" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.07532980395145875" LOG_CI_START="-0.7956326995167343" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.5116076858711411" STUDY_ID="STD-Calvey-1985" TOTAL_1="10" TOTAL_2="16" VAR="0.2617424242424242" WEIGHT="3.031977357380161"/>
<DICH_DATA CI_END="0.8509710702846247" CI_START="0.48133246158767884" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="-0.07008520399215948" LOG_CI_START="-0.3175548480400661" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.14536489390823484" STUDY_ID="STD-Hayashi-1991" TOTAL_1="35" TOTAL_2="32" VAR="0.021130952380952375" WEIGHT="13.94705392467433"/>
<DICH_DATA CI_END="1.0262215403426131" CI_START="0.5379926129660217" EFFECT_SIZE="0.7430340557275542" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.011241126236103013" LOG_CI_START="-0.26922368747509673" LOG_EFFECT_SIZE="-0.12899128061949686" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.1647464198971772" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.027141382868937025" WEIGHT="12.796319374598312"/>
<DICH_DATA CI_END="1.0872319887872215" CI_START="0.281360915490093" EFFECT_SIZE="0.5530864197530864" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.03632222182358812" LOG_CI_START="-0.5507362315845998" LOG_EFFECT_SIZE="-0.2572070048805058" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.3448410415181811" STUDY_ID="STD-Hwang-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.1189153439153439" WEIGHT="5.662553232628741"/>
<DICH_DATA CI_END="1.1607310698305546" CI_START="0.17017797604605062" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06473160955968839" LOG_CI_START="-0.7690966457824134" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4897948447043822" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" VAR="0.2398989898989899" WEIGHT="3.263867000173478"/>
<DICH_DATA CI_END="0.6592784371239883" CI_START="0.14491174699935966" EFFECT_SIZE="0.3090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.1809311283988846" LOG_CI_START="-0.8388964078330552" LOG_EFFECT_SIZE="-0.5099137681159699" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" VAR="0.14937611408199641" WEIGHT="4.7783825398602895"/>
<DICH_DATA CI_END="1.1811049088991443" CI_START="0.6586075521977022" EFFECT_SIZE="0.8819776714513556" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" LOG_CI_END="0.07228847452503065" LOG_CI_START="-0.18137329357706702" LOG_EFFECT_SIZE="-0.054542409526018194" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14900217822917508" STUDY_ID="STD-Marchesini-2003" TOTAL_1="33" TOTAL_2="79" VAR="0.022201649117038855" WEIGHT="13.72715080692771"/>
<DICH_DATA CI_END="1.2966045715093941" CI_START="0.687931639484824" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.11280754848530533" LOG_CI_START="-0.16245471593536961" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.16169041669088863" STUDY_ID="STD-Michel-1985" TOTAL_1="36" TOTAL_2="34" VAR="0.0261437908496732" WEIGHT="12.973989165362578"/>
<DICH_DATA CI_END="2.0399051715516237" CI_START="0.3873334250087359" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.30960997898026926" LOG_CI_START="-0.41191502387503187" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.4238273582835701" STUDY_ID="STD-Muto-2005" TOTAL_1="27" TOTAL_2="12" VAR="0.1796296296296297" WEIGHT="4.1368373770235465"/>
<DICH_DATA CI_END="1.2986549372647005" CI_START="0.7829147542861673" EFFECT_SIZE="1.0083333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11349377097339829" LOG_CI_START="-0.10628552243574782" LOG_EFFECT_SIZE="0.003604124268825241" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.1290994448735806" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.016666666666666677" WEIGHT="14.945308646611938"/>
<DICH_DATA CI_END="1.457733319758401" CI_START="0.6583808161878604" EFFECT_SIZE="0.9796650717703349" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.1636780806687439" LOG_CI_START="-0.1815228320259398" LOG_EFFECT_SIZE="-0.008922375678597928" MODIFIED="2014-12-20 03:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.20277272488893378" STUDY_ID="STD-Vilstrup-1990" TOTAL_1="38" TOTAL_2="39" VAR="0.04111677795888322" WEIGHT="10.73656057475891"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.5151895468094505" CI_END="1.2984851486129374" CI_START="0.33636697652435676" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6608838956282063" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="45.60477070574108" I2_Q="8.932525837036163" ID="CMP-001.16" LOG_CI_END="0.11343698676290727" LOG_CI_START="-0.4731866484783007" LOG_EFFECT_SIZE="-0.1798748308576967" METHOD="MH" MODIFIED="2014-12-21 17:23:53 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.13773303032765294" P_Q="0.2946868243759244" P_Z="0.22938021323341795" Q="1.0980868956687164" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1970342506925219" TOTALS="YES" TOTAL_1="108" TOTAL_2="87" WEIGHT="100.00000000000003" Z="1.2019569926171103">
<NAME>Hepatic encephalopathy: trials with lactulose or neomycin control</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.246341740238634" CI_END="2.4808410960534726" CI_START="0.03340367376153972" DF="1" EFFECT_SIZE="0.2878701211080977" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="76.45031744562786" ID="CMP-001.16.01" LOG_CI_END="0.39459894753813113" LOG_CI_START="-1.4762057665230324" LOG_EFFECT_SIZE="-0.5408034094924505" MODIFIED="2014-12-21 17:04:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03933513350883744" P_Z="0.25714947950879574" STUDIES="2" TAU2="1.9173705903284433" TOTAL_1="52" TOTAL_2="36" WEIGHT="48.233949254219304" Z="1.1331543023758024">
<NAME>Lactulose</NAME>
<DICH_DATA CI_END="0.6346111589572913" CI_START="0.010942833806853684" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.19749229556531525" LOG_CI_START="-1.9608701965299344" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2014-12-21 15:33:21 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="0.0" SE="1.0358169078880044" STUDY_ID="STD-Fiaccadori-1984" TOTAL_1="32" TOTAL_2="16" VAR="1.0729166666666667" WEIGHT="9.349908947832844"/>
<DICH_DATA CI_END="1.270789059948241" CI_START="0.3497389601878903" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10407346738853614" LOG_CI_START="-0.45625598549989865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-12-21 15:33:17 +0100" MODIFIED_BY="[Empty name]" ORDER="867" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Rossi_x002d_Fanelli-1986" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="38.88404030638646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0036825115933186298" CI_END="1.6812577768232302" CI_START="0.5343128831495276" DF="1" EFFECT_SIZE="0.9477962281271144" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.22563430622297645" LOG_CI_START="-0.2722043541470667" LOG_EFFECT_SIZE="-0.023285023962045147" MODIFIED="2014-12-21 17:04:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9516111560171643" P_Z="0.8545282932523393" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="51" WEIGHT="51.76605074578072" Z="0.18334376968971466">
<NAME>Neomycin</NAME>
<DICH_DATA CI_END="1.7228482135078165" CI_START="0.5153929290000219" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.23624701689100977" LOG_CI_START="-0.2878615441035807" LOG_EFFECT_SIZE="-0.025807263606285505" MODIFIED="2014-12-21 15:34:06 +0100" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.307863963107441" STUDY_ID="STD-Cerra-1985" TOTAL_1="40" TOTAL_2="35" VAR="0.09478021978021979" WEIGHT="40.68998163898232"/>
<DICH_DATA CI_END="6.254983025344274" CI_START="0.159872536176061" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.796226135450811" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-21 15:34:13 +0100" MODIFIED_BY="[Empty name]" ORDER="870" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Strauss-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.875" WEIGHT="11.076069106798396"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.62058344798235" CI_END="16.455596508623938" CI_START="0.7000440147409733" CI_STUDY="90" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3940597880495043" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="11" I2="77.97451180078194" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="1.2163136299125747" LOG_CI_START="-0.15487465318833946" LOG_EFFECT_SIZE="0.5307194883621177" METHOD="MH" MODIFIED="2014-12-21 17:23:50 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.003469856742279065" P_Q="1.0" P_Z="0.12921337945399752" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.9206676611465041" TOTALS="YES" TOTAL_1="442" TOTAL_2="503" WEIGHT="99.99999999999999" Z="1.5172111604263483">
<NAME>Nausea and diarrhoea</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>BCAA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.17649876640149" CI_START="0.4089186219774277" EFFECT_SIZE="1.1397058823529411" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5019486910123384" LOG_CI_START="-0.3883631114121905" LOG_EFFECT_SIZE="0.05679278980007395" MODIFIED="2014-12-01 21:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="495" O_E="0.0" SE="0.6231614323576103" STUDY_ID="STD-Hayashi-1991" TOTAL_1="34" TOTAL_2="31" VAR="0.3883301707779886" WEIGHT="28.096088740958155"/>
<DICH_DATA CI_END="7.4392927592348705" CI_START="1.012940811551129" EFFECT_SIZE="2.7450980392156863" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8715316498790296" LOG_CI_START="0.005584069281573808" LOG_EFFECT_SIZE="0.4385578595803017" MODIFIED="2014-12-01 21:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="496" O_E="0.0" SE="0.6061080322671129" STUDY_ID="STD-Horst-1984" TOTAL_1="17" TOTAL_2="20" VAR="0.36736694677871146" WEIGHT="28.353508187211354"/>
<DICH_DATA CI_END="6.051233317724821" CI_START="0.6278382329615925" EFFECT_SIZE="1.9491525423728813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.7818438983706908" LOG_CI_START="-0.20215224094775586" LOG_EFFECT_SIZE="0.28984582871146747" MODIFIED="2014-12-01 21:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6887344882345547" STUDY_ID="STD-Marchesini-2003" TOTAL_1="59" TOTAL_2="115" VAR="0.47435519528371406" WEIGHT="27.08692646262464"/>
<DICH_DATA CI_END="812.3939330685698" CI_START="7.573562598948836" EFFECT_SIZE="78.4392523364486" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="0" LOG_CI_END="2.909766671447835" LOG_CI_START="0.8793002194079574" LOG_EFFECT_SIZE="1.894533445427896" MODIFIED="2014-12-01 21:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.4211969100729789" STUDY_ID="STD-Muto-2005" TOTAL_1="320" TOTAL_2="326" VAR="2.019800657200983" WEIGHT="16.46347660920584"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-01 21:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="497" O_E="0.0" SE="0.0" STUDY_ID="STD-Plauth-1993" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.0249220031870374" CI_END="2.093433077865765" CI_START="-0.9016396278603614" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5958967250027017" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2015-09-09 11:54:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="18" P_CHI2="0.599019650109847" P_Q="1.0" P_Z="0.4354467900288985" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="104" UNITS="" WEIGHT="100.0" Z="0.779905020187154">
<NAME>Albumin</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>BCAA</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.4710534072257366" CI_START="-3.4710534072257366" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="29.0" MODIFIED="2014-12-01 21:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="6.0" SD_2="5.0" SE="1.7709781580707415" STUDY_ID="STD-Les-2011" TOTAL_1="18" TOTAL_2="22" WEIGHT="18.61367623344035"/>
<CONT_DATA CI_END="2.253966936698267" CI_START="-2.253966936698267" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="34.0" MODIFIED="2014-12-01 21:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="566" SD_1="4.3" SD_2="4.9" SE="1.1500042625666953" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" WEIGHT="44.14277845389081"/>
<CONT_DATA CI_END="4.0538717777092685" CI_START="-0.8538717777092661" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="34.3" MODIFIED="2014-12-01 21:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="4.8" SD_2="5.4" SE="1.2519984025548914" STUDY_ID="STD-Marchesini-2003" TOTAL_1="24" TOTAL_2="48" WEIGHT="37.24354531266883"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.729765473954188" CI_END="1.5619227483626896" CI_START="0.0659625727082026" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.8139426605354461" ESTIMABLE="YES" I2="65.09455737601468" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2014-12-21 17:23:42 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.05698988084962742" P_Q="1.0" P_Z="0.032940437489948" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.28207590213355244" TOTALS="YES" TOTAL_1="53" TOTAL_2="55" UNITS="" WEIGHT="100.00000000000001" Z="2.1328085146815328">
<NAME>Nitrogen balance</NAME>
<GROUP_LABEL_1>BCAA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>BCAA</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5921527080204276" CI_START="0.6145983468318934" EFFECT_SIZE="1.6033755274261605" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="-6.0" MODIFIED="2014-12-01 21:01:52 +0100" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="6.0" SD_2="6.0" SE="0.5044874234392138" STUDY_ID="STD-Cerra-1985" TOTAL_1="12" TOTAL_2="10" WEIGHT="27.14229756634562"/>
<CONT_DATA CI_END="0.8839195420701141" CI_START="-0.7878370385831311" EFFECT_SIZE="0.04804125174349152" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.1" MODIFIED="2014-12-01 21:01:52 +0100" MODIFIED_BY="[Empty name]" ORDER="355" SD_1="1.9" SD_2="2.1" SE="0.42647635207581563" STUDY_ID="STD-Egberts-1985" TOTAL_1="11" TOTAL_2="11" WEIGHT="31.391006525373015"/>
<CONT_DATA CI_END="1.3924082913689821" CI_START="0.3616213622604736" EFFECT_SIZE="0.8770148268147279" ESTIMABLE="YES" MEAN_1="3.36" MEAN_2="1.64" MODIFIED="2014-12-01 21:01:52 +0100" MODIFIED_BY="[Empty name]" ORDER="567" SD_1="1.72" SD_2="2.11" SE="0.26296068122660016" STUDY_ID="STD-Marchesini-1990" TOTAL_1="30" TOTAL_2="34" WEIGHT="41.46669590828137"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-05-05 16:12:37 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-05-05 16:12:37 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram. BCAA: branched-chain amino acids.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAhMAAAMFCAYAAADOW3QWAAB2oUlEQVR42uy9D2Qd2f///2GtVVVV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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-02-19 09:08:15 +0100" MODIFIED_BY="Chavdar S Pavlov" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. CHBG: Cochrane Hepato-Biliary Group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAM1CAIAAAByu1YpAAA52UlEQVR42u3dwW4jxdqHcUtIiIUX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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-02-19 09:08:15 +0100" MODIFIED_BY="Chavdar S Pavlov" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. CHBG: Cochrane Hepato-Biliary Group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAFkCAMAAADG9sXiAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="BCAA TSA1.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-09-08 12:39:17 +0200" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Trial sequential analysis of branched-chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for mortality in people with hepatic encephalopathy.</B> The blue line (Z-curve) shows the cumulative meta-analysis adding the results of individual trials based on the year of publication. The vertical green line represents the 5% level of significance. The monitoring boundary (and futility) was ignored because the number of events and participants included in the analysis was insufficient. In the sequential analysis, we set alpha to 5%, power to 80%, control group incidence to 25%, relative risk reduction to 5%, and heterogeneity correction to 17%. The estimated information size was 23,485 participants. In total, the number of participants randomised was 367 in the BCAA group and 393 in the control groups.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu4AAAHhCAYAAAAxozuCAABNqklEQVR42uzdCZxN9f/HcfVLfr9Q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==
</FILE>
</FIGURE>
<FIGURE FILENAME="BCAA TSA1.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-09-08 12:40:26 +0200" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Trial sequential analysis of branched-chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for hepatic encephalopathy. </B>The blue line (Z-curve) shows the cumulative meta-analysis adding the results of individual trials based on the year of publication. The vertical line represents the 5% level of significance. The monitoring boundary (inward sloping red line) shows the significance level after adjusting for the cumulative analysis. The horizontal green line shows the required information size (the number of participants needed to determine if firm evidence was established). We conducted the trial sequential analysis with alpha set to 5%, power to 80%, control group event rate to 63%, relative risk reduction to 45%, and heterogeneity correction to 47%. The estimated required information size was 186 participants (diversity adjusted). In total, the cumulative meta-analysis included 402 participants in the BCAA group and 425 in the control groups.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu4AAAHhCAYAAAAxozuCAABybUlEQVR42uzdBZhU1RsGcDokRGlQ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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-09-09 11:59:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-09-09 11:59:30 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2015-09-09 11:59:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">*Downgrading of the quality of evidence due to imprecision</TITLE>
<DATE_SUBMITTED>
<DATE DAY="29" MONTH="7" YEAR="2015"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-09-09 11:59:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We received a suggestion to downgrade the quality of the evidence for the outcome 'nausea and diarrhoea' based on imprecision.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-09-08 12:58:11 +0200" MODIFIED_BY="[Empty name]">
<P>We agree with the comment and have downgraded the evidence.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-09-08 12:58:24 +0200" MODIFIED_BY="[Empty name]">
<P>Lise Lotte Gluud incorporated the change.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2017-05-10 11:54:55 +0200" MODIFIED_BY="Sarah  Klingenberg">
<APPENDIX ID="APP-01" MODIFIED="2017-05-10 11:54:55 +0200" MODIFIED_BY="Sarah  Klingenberg" NO="1">
<TITLE MODIFIED="2014-03-21 13:29:49 +0100" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-10 11:54:55 +0200" MODIFIED_BY="Sarah  Klingenberg">
<TABLE COLS="3" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Search terms</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>May 2017.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>branched-chain AND (encephalopath* OR liver disease* OR cirrho*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 4 of 12, 2017.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor: [Amino Acids, Branched-Chain] explode all trees</P>
<P>#2 branched chain</P>
<P>#3 #1 or #2</P>
<P>#4 MeSH descriptor: [Hepatic Encephalopathy] explode all trees</P>
<P>#5 MeSH descriptor: [Liver Diseases] explode all trees</P>
<P>#6 MeSH descriptor: [Fibrosis] explode all trees</P>
<P>#7 encephalopath* or liver disease* or cirrho*</P>
<P>#8 #4 or #5 or #6 or #7</P>
<P>#9 #3 and #8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE Ovid</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to May 2017.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Amino Acids, Branched-Chain/</P>
<P>2. branched chain.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>3. 1 or 2</P>
<P>4. exp Hepatic Encephalopathy/</P>
<P>5. exp Liver Diseases/</P>
<P>6. exp Fibrosis/</P>
<P>7. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>8. 4 or 5 or 6 or 7</P>
<P>9. 3 and 8</P>
<P>10. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>11. 9 and 10</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Embase Ovid</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to May 2017.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp branched chain amino acid/</P>
<P>2. branched chain.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>3. 1 or 2</P>
<P>4. exp hepatic encephalopathy/</P>
<P>5. exp liver disease/</P>
<P>6. exp fibrosis/</P>
<P>7. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>8. 4 or 5 or 6 or 7</P>
<P>9. 3 and 8</P>
<P>10. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>11. 9 and 10</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded and Conference Proceedings Citation Index &#8211; Science (Web of Science)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to May 2017.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#5 #4 AND #3</P>
<P>#4 TS=(random* or blind* or placebo* or meta-analysis)</P>
<P>#3 #2 AND #1</P>
<P>#2 TS=(encephalopath* or liver disease* or cirrho*)</P>
<P>#1 TS=branched chain</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lilacs (Bireme)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1982 to May 2017</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>aminoacid$ OR (amino acid$) [Words] and (encephalopath$ OR liver disease$ OR cirrho$) [Words]</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2011-11-14 18:28:24 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 randomised clinical trials (40 references) included in the quantitative and qualitative analyses&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;74 records records referring to potentially eligible trials assessed&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;748 records screened&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;446 duplicate references removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1196 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;20 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;674 records excluded because they were not randomised (observational studies, meta-analyses, and narrative reviews), did not assess BCAA or did not include people with hepatic encephalopathy&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="140"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;34 references excluded because they did not assess BCAA supplements for hepatic encephalopathy&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>